# EDGAR Filing Document

**Accession Number:** 0000738214
**File Stem:** 0001437749-26-015362
**Filing Date:** 2026-5
**Character Count:** 201202
**Document Hash:** 02610c06b271cc11a7a0107a200abeb8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-015362.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001437749-26-015362

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 83

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AEMETIS, INC
- **CENTRAL INDEX KEY:** 0000738214
- **STANDARD INDUSTRIAL CLASSIFICATION:** INDUSTRIAL ORGANIC CHEMICALS [2860]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 261407544
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36475
- **FILM NUMBER:** 26951126

**BUSINESS ADDRESS:**
- **STREET 1:** 20400 STEVENS CREEK BLVD
- **STREET 2:** SUITE 700
- **CITY:** CUPERTINO
- **STATE:** CA
- **ZIP:** 95014
- **BUSINESS PHONE:** 408-517-3304

**MAIL ADDRESS:**
- **STREET 1:** 20400 STEVENS CREEK BLVD
- **STREET 2:** SUITE 700
- **CITY:** CUPERTINO
- **STATE:** CA
- **ZIP:** 95014

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AE BIOFUELS, INC.
- **DATE OF NAME CHANGE:** 20110714

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AE Biofuels, Inc.
- **DATE OF NAME CHANGE:** 20071212

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARWICH II LTD
- **DATE OF NAME CHANGE:** 19840123

?xml version='1.0' encoding='ASCII'? amtx20260331_10q.htm

------

[**Table of Contents**](#toc)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2026

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-36475

## Aemetis, Inc.
*(Exact name of registrant as specified in its charter)*

------

---

| | |
|:---|:---|
| **Delaware** | **26-1407544** |
| *(State or other jurisdiction* | *(I.R.S. Employer* |
| *of incorporation or organization)* | *Identification No.)* |

---

**20400 Stevens Creek Blvd., Suite 700**

**Cupertino, CA 95014**

**(408) 213-0940**

*(Address and telephone number of principal executive offices)*

---

| | | |
|:---|:---|:---|
| Title of each class of registered securities | Trading Symbol | Name of each exchange on which registered |
| **Common Stock, $0.001 par value** | **AMTX** | **NASDAQ** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☑ Non-accelerated filer ☐ Smaller reporting company ☑ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

The number of shares outstanding of the registrant's Common Stock on April 30, 2026, was 70,366,477 shares.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1

------

[**Table of Contents**](#toc)

**AEMETIS, INC.**

**FORM 10-Q**

Quarterly Period Ended March 31, 2026

---

| | | |
|:---|:---|:---|
| **INDEX** | **INDEX** | **INDEX** |
| [**PART I--FINANCIAL INFORMATION**](#part1) | [**PART I--FINANCIAL INFORMATION**](#part1) | [**PART I--FINANCIAL INFORMATION**](#part1) |
| [Item 1](#item1fs) | [Financial Statements.](#item1fs) | [4](#item1fs) |
| [Item 2.](#item2mda) | [Management's Discussion and Analysis of Financial Condition and Results of Operations.](#item2mda) | [21](#item2mda) |
| [Item 3.](#item3qqd) | [Quantitative and Qualitative Disclosures about Market Risk.](#item3qqd) | [25](#item3qqd) |
| [Item 4.](#item4controls) | [Controls and Procedures.](#item4controls) | [25](#item4controls) |
| [**PART II--OTHER INFORMATION**](#part2) | [**PART II--OTHER INFORMATION**](#part2) | [**PART II--OTHER INFORMATION**](#part2) |
| [Item 1.](#item1legal) | [Legal Proceedings](#item1legal). | [26](#item1legal) |
| [Item 1A.](#item1aRisk) | [Risk Factors.](#item1aRisk) | [26](#item1aRisk) |
| [Item 2.](#item2unregistered) | [Unregistered Sales of Equity Securities and Use of Proceeds.](#item2unregistered) | [26](#item2unregistered) |
| [Item 3.](#item3defaults) | [Defaults Upon Senior Securities.](#item3defaults) | [26](#item3defaults) |
| [Item 4.](#item4mine) | [Mine Safety Disclosures.](#item4mine) | [26](#item4mine) |
| [Item 5.](#item5other) | [Other Information.](#item5other) | [26](#item5other) |
| [Item 6.](#item6exhibits) | [Exhibits.](#item6exhibits) | [26](#item6exhibits) |
| [Signatures](#signatures) | [Signatures](#signatures) | [27](#signatures) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

[**Table of Contents**](#toc)

**SPECIAL NOTE REGARDING FORWARD**-**LOOKING STATEMENTS**

We make forward-looking statements in this Quarterly Report on Form 10-Q, including statements regarding our assumptions, projections, expectations, targets, intentions, or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this Quarterly Report on Form 10-Q include, without limitation, statements regarding management's plans; trends in market conditions with respect to prices for inputs for our products and prices for our products; our ability to leverage approved feedstock pathways; our ability to leverage our location and infrastructure; our ability to incorporate lower-cost, non-food advanced biofuels feedstock at the Keyes Plant; our ability to expand into alternative markets for biodiesel and its byproducts, including continuing to expand our sales into international markets; our ability to maintain and expand strategic relationships with suppliers; our ability to access governmental carbon reduction incentives; our ability to supply gas into transportation markets; our ability to continue to develop, maintain, and protect new and existing intellectual property rights; our ability to adopt, develop and commercialize new technologies; our ability to extend or refinance our senior debt on terms reasonably acceptable to us or at all; our ability to continue to fund operations and our future sources of liquidity and capital resources; our ability to fund, develop, build, maintain and operate digesters, facilities and pipelines for our California Dairy Renewable Natural Gas segment; our ability to fund, develop and operate our carbon capture sequestration projects, including obtaining required permits; our ability to receive awarded grants by meeting all of the required conditions, including meeting the minimum contributions; our ability to obtain additional financing under the EB-5 program; our ability to generate and sell or utilize various credits, including California Low Carbon Fuel Standard ("LCFS"), federal Renewable Fuel Standard D3 RINs, federal Section 45Z production tax credits, and investment tax credits; our ability to improve margins; and our ability to raise additional debt and equity funding at the parent, subsidiary, or project level. Words or phrases such as "anticipates," "may," "will," "should," "could," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "will likely result," "will continue" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, the risks set forth under the caption "Risk Factors" below, which are incorporated herein by reference, as well as those business risks and factors described elsewhere in this report and in our other filings with the Securities and Exchange Commission (the "SEC"), including without limitation, our most recent Annual Report on Form 10-K and subsequent Form 10-Q filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

[**Table of Contents**](#toc)

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**AEMETIS, INC.**

**CONSOLIDATED CONDENSED BALANCE SHEETS**

(In thousands except for par value)

---

| | | |
|:---|:---|:---|
|  | ***March 31, 2026*** | ***December 31, 2025*** |
|  | ***Unaudited*** |  |
| Assets |  |  |
| Current assets: |  |  |
| Cash and cash equivalents ($1,005 and $3,154 respectively from VIE) | $4797 | $4894 |
| Accounts receivable ($708 and $81 respectively from VIE) | 6584 | 484 |
| Inventories ($260 and $307 respectively from VIE) | 10384 | 11627 |
| Prepaid expenses ($68 and $38 respectively from VIE) | 1144 | 1531 |
| Other current assets ($1,635 and $560 respectively from VIE) | 11778 | 8334 |
| Total current assets | 34687 | 26870 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restricted cash ($2,068 and $2,992 respectively from VIE) | 2068 | 2992 |
| Property, plant and equipment, net ($102,923 and $102,120 respectively from VIE) | 222743 | 219717 |
| Operating lease right-of-use ($1,054 and $1,058 respectively from VIE) | 2145 | 2256 |
| Other assets ($3,328 and $3,333 respectively from VIE) | 8686 | 8006 |
| Total assets | $**270329** | $**259841** |
| **Liabilities and stockholders' deficit** |  |  |
| Current liabilities: |  |  |
| Accounts payable ($3,995 and $4,959 respectively from VIE) | $23719 | $23418 |
| Current portion of long-term debt ($1,101 and $1,077 respectively from VIE) | 293828 | 279143 |
| Short term borrowings ($300 and $300 respectively from VIE) | 48802 | 38726 |
| Other current liabilities ($802 and $387 respectively from VIE) | 29897 | 29971 |
| Total current liabilities | 396246 | 371258 |
| Long term liabilities: |  |  |
| EB-5 notes | 14500 | 16000 |
| Other long-term debt ($47,536 and $47,875 respectively from VIE) | 47550 | 47895 |
| Series A preferred units ($128,596 and $126,910 respectively from VIE) | 128596 | 126910 |
| Other long-term liabilities ($950 and $940 respectively from VIE) | 4575 | 4609 |
| Total long term liabilities | 195221 | 195414 |
| Stockholders' deficit: |  |  |
| Common stock, $0.001 par value; 140,000 authorized; 69,280 and 66,189 shares issued and outstanding each period, respectively | 69 | 66 |
| Additional paid-in capital | 348741 | 340402 |
| Accumulated deficit | (661656) | (639943) |
| Accumulated other comprehensive loss | (8292) | (7356) |
| &nbsp;&nbsp;&nbsp; Total stockholders' deficit | (321138) | (306831) |
| Total liabilities and stockholders' deficit | $**270329** | $**259841** |

---

*The accompanying notes are an integral part of the consolidated financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

[**Table of Contents**](#toc)

**AEMETIS, INC.**

**CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

(Unaudited, in thousands except for loss per share)

---

| | | |
|:---|:---|:---|
|  | ***For the three months ended March 31,*** | ***For the three months ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Revenues | $54619 | $42886 |
| Cost of goods sold | 51863 | 47966 |
| Gross profit (loss) | 2756 | (5080) |
| Selling, general and administrative expenses | 9091 | 10475 |
| Operating loss | (6335) | (15555) |
| Other expense (income): |  |  |
| Interest expense |  |  |
| Interest rate expense | 12403 | 11018 |
| Debt related fees and amortization expense | 1971 | 2675 |
| Accretion and other expenses of Series A preferred units | 1613 | 2279 |
| Total interest expense | 15987 | 15972 |
| Other income | (478) | (215) |
| Other expense (income), net | 15509 | 15757 |
| Loss before income taxes | (21844) | (31312) |
| Income tax benefit | (131) | (6783) |
| Net loss | $(21713) | $(24529) |
| Other comprehensive loss |  |  |
| Foreign currency translation gain (loss) | (936) | 13 |
| Comprehensive loss | $(22649) | $(24516) |
| Net loss per share |  |  |
| Basic | $(0.33) | $(0.47) |
| Diluted | $(0.33) | $(0.47) |
| Weighted average shares outstanding |  |  |
| Basic | 66802 | 52584 |
| Diluted | 66802 | 52584 |

---

*The accompanying notes are an integral part of the consolidated financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5

------

[**Table of Contents**](#toc)

**AEMETIS, INC.**

**CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS**

(Unaudited, in thousands)

---

| | | |
|:---|:---|:---|
|  | ***For the three months ended March 31,*** | ***For the three months ended March 31,*** |
|  | ***2026*** | ***2025*** |
| **Operating activities:** |  |  |
| Net loss | $(21713) | $(24529) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| Share-based compensation | 1704 | 2308 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock issued for services | 50 |  |
| Depreciation | 2523 | 2357 |
| Bad debt expense | 276 |  |
| Intangibles and other amortization expense | 12 | 12 |
| Debt related fees and amortization expense | 1971 | 2675 |
| Accretion and other expenses of Series A preferred units | 1613 | 2279 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss on asset sales | 2 |  |
| Changes in operating assets and liabilities: |  |  |
| Accounts receivable | (6558) | 751 |
| Inventories | 830 | 2505 |
| Prepaid expenses | 383 | (57) |
| Tax credit sale receivable |  | 12300 |
| Other assets | (3690) | 516 |
| Accounts payable | 1155 | (650) |
| Accrued interest expense and fees | 11799 | (206) |
| Other liabilities | (914) | (101) |
| Net cash provided by (used in) operating activities | (10557) | 160 |
| **Investing activities:** |  |  |
| Capital expenditures | (6548) | (1825) |
| Grant proceeds for capital expenditures | 1440 |  |
| Proceeds from sale of fixed assets | 2 |  |
| Net cash used in investing activities | (5106) | (1825) |
| **Financing activities:** |  |  |
| Proceeds from borrowings | 15984 | 3800 |
| Repayments of borrowings | (7877) | (5181) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Payments on Series A preferred financing |  | (2200) |
| Lender debt renewal and waiver fee payments |  | (295) |
| Payments on finance leases |  | (9) |
| Proceeds from sales of common stock | 6588 | 5087 |
| Proceeds from exercise of stock options |  | 50 |
| Net cash provided by financing activities | 14695 | 1252 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (53) | 6 |
| Net change in cash, cash equivalents, and restricted cash for period | (1021) | (407) |
| Cash, cash equivalents, and restricted cash at beginning of period | 7886 | 3831 |
| Cash, cash equivalents and restricted cash at end of period | $6865 | $3424 |
| Supplemental disclosures of cash flow information, cash paid: |  |  |
| Cash paid for interest | $1209 | $10302 |
| Income taxes paid |  |  |
| Supplemental disclosures of cash flow information, non-cash transactions: |  |  |
| Lender debt extension, waiver, and other fees added to debt | 1700 | 2126 |
| Capital expenditures in accounts payable and accruals | 7417 | 10671 |
| Accrued capital expenditures in construction financing | 4121 |  |
| Subordinated debt extension fees added to debt |  | 340 |
| Fair value of warrants issued to subordinated debt holders |  | 304 |

---

*The accompanying notes are an integral part of the consolidated financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6

------

[**Table of Contents**](#toc)

**AEMETIS, INC.**

**CONSOLIDATED STATEMENTS OF STOCKHOLDERS**' **DEFICIT**

(Unaudited, in thousands)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| ***For the three months ended March 31, 2026*** | ***For the three months ended March 31, 2026*** | ***For the three months ended March 31, 2026*** | ***For the three months ended March 31, 2026*** | ***For the three months ended March 31, 2026*** | ***For the three months ended March 31, 2026*** | ***For the three months ended March 31, 2026*** |
|  | ***Common Stock*** | ***Common Stock*** | ***Additional*** |  | ***Accumulated Other*** | ***Total*** |
|  |  |  | ***Paid-in*** | ***Accumulated*** | ***Comprehensive*** | ***Stockholders'*** |
| **Description** | ***Shares*** | ***Dollars*** | ***Capital*** | ***Deficit*** | ***Loss*** | ***deficit*** |
| Balance at December 31, 2025 | 66189 | $66 | $340402 | $(639943) | $(7356) | (306831) |
| Issuance of common stock | 2564 | 3 | 6585 |  |  | 6588 |
| Stock-based compensation | *379* |  | 1704 |  |  | 1704 |
| Issuance of common stock for services | 35 |  | 50 |  |  | 50 |
| Issuance and exercise of warrants | 113 |  |  |  |  |  |
| Foreign currency translation loss | *-* |  |  |  | (936) | (936) |
| Net loss | *-* |  |  | (21713) |  | (21713) |
| Balance at March 31, 2026 | 69280 | 69 | $348741 | $(661656) | $(8292) | $(321138) |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| ***For the three months ended March 31, 2025*** | ***For the three months ended March 31, 2025*** | ***For the three months ended March 31, 2025*** | ***For the three months ended March 31, 2025*** | ***For the three months ended March 31, 2025*** | ***For the three months ended March 31, 2025*** | ***For the three months ended March 31, 2025*** |
|  | ***Common Stock*** | ***Common Stock*** | ***Additional*** |  | ***Accumulated Other*** | ***Total*** |
|  |  |  | ***Paid-in*** | ***Accumulated*** | ***Comprehensive*** | ***Stockholders'*** |
| **Description** | ***Shares*** | ***Dollars*** | ***Capital*** | ***Deficit*** | ***Loss*** | ***deficit*** |
| Balance at December 31, 2024 | 51139 | $51 | $305329 | $(562942) | $(6366) | $(263928) |
| Issuance of common stock | 2370 | 3 | 5084 |  |  | 5087 |
| Stock options exercised | 51 |  | 50 |  |  | 50 |
| Stock-based compensation | *369* |  | 2308 |  |  | 2308 |
| Issuance and exercise of warrants | 113 |  | 304 |  |  | 304 |
| Foreign currency translation gain | *-* |  |  |  | 13 | 13 |
| Net loss | *-* |  |  | (24529) |  | (24529) |
| Balance at March 31, 2025 | 54042 | $54 | $313075 | $(587471) | $(6353) | $(280695) |

---

*The accompanying notes are an integral part of the consolidated financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

***1.* General**

***Nature of Activities***

Founded in *2006* and headquartered in Cupertino, California, Aemetis, Inc. (collectively with its subsidiaries on a consolidated basis referred to herein as "Aemetis," the "Company," "we," "our" or "us") is an international renewable natural gas and renewable fuels company focused on the operation, acquisition, development, and commercialization of innovative technologies to produce low and negative carbon intensity renewable fuels that lower fuel costs and reduce emissions. We do this by building a local circular bioeconomy using agricultural products and waste materials to produce low carbon, advanced renewable fuels that reduce greenhouse gas ("GHG") emissions and improve air quality. Our current operations include:

► **California Ethanol** – We own and operate a *65* million gallon per year capacity ethanol production facility in Keyes, California (the "Keyes Plant"). In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains ("WDG"), Distillers Corn Oil ("DCO"), and Condensed Distillers Solubles ("CDS"). WDG and CDS are sold to local dairies or feedlots as animal feed, and DCO is sold to commodity aggregators as feedstock for the production of Renewable Diesel. The Keyes Plant also sells CO₂ captured from the fermentation process to produce commercial grade CO₂ for the food, beverage, and other industries. We are implementing several energy efficiency initiatives at the Keyes Plant focused on reducing operating costs and lowering the carbon intensity of our ethanol to increase revenues.

► **California Dairy Renewable Natural Gas** – We produce Renewable Natural Gas ("RNG") in central California. We currently have *twelve* anaerobic digesters that produce biogas from dairy waste, a *36*-mile biogas collection pipeline leading to a central RNG production facility, and an interconnection to inject the RNG into the utility natural gas pipeline for delivery for use as transportation fuel. We are actively expanding our RNG production, with *two* additional dairy digesters under construction, agreements with over *fifty* dairies, and environmental review completed for an additional *24* miles of biogas pipeline. We are also building our own RNG fuel dispensing station, which is planned to begin operating in *2026.*

► **India Biodiesel** – We own and operate a plant in Kakinada, India ("Kakinada Plant") with a capacity to produce about *80* million gallons per year of high-quality distilled biodiesel from a variety of vegetable oils and animal waste feedstocks. The Kakinada Plant is *one* of the largest biodiesel production facilities in India. The Kakinada Plant refines and converts the crude glycerin, a byproduct from biodiesel production, into refined glycerin, which meets the quality standards for selling into the pharmaceutical, personal care, paint, adhesive, and other sectors, supporting their manufacturing and production needs.

Our current and planned businesses produce renewable fuels and reduce emissions, generating revenues from biofuel sales, federal Renewable Fuel Standard ("RFS") credits (referred to as *"D3* RINs"), federal Section *45Z* production tax credits ("Section *45Z* PTCs," "PTCs"), California Low Carbon Fuel Standard ("LCFS") credits, and other investment and production tax credits.

***Basis of Presentation and Consolidation***

These consolidated financial statements include the accounts of Aemetis, Inc. and its subsidiaries. We consolidate all entities in which we hold a "controlling financial interest." For voting interest entities, we are considered to hold a controlling financial interest when we are able to exercise control over the investees' operating and financial decisions. For variable interest entities (VIEs), the determination of which is based on the amount and characteristics of the entity's equity, we are considered to hold a controlling financial interest when we are determined to be the primary beneficiary. A primary beneficiary is the party that has both: (*1*) the power to direct the activities that most significantly impact that VIE's economic performance, and (*2*) the obligation to absorb the losses of, or the right to receive the benefits from, the VIE that could potentially be significant to that VIE.

All intercompany balances and transactions have been eliminated in consolidation.

The accompanying consolidated condensed balance sheet as of *March 31, 2026*, the consolidated condensed statements of operations and comprehensive loss for the *three* months ended *March 31, 2026* and *2025*, the consolidated condensed statements of cash flows for the *three* months ended *March 31, 2026* and *2025*, and the consolidated statements of stockholders' deficit for the *three* months ended *March 31, 2026* and *2025*, are unaudited. The consolidated condensed balance sheet as of *December 31, 2025*, is derived from the *2025* audited consolidated financial statements and notes thereto.

The financial statements in this report should be read in conjunction with the *2025* audited consolidated financial statements and notes thereto included in our annual report on Form *10*-K for the year ended *December 31, 2025*. There have been *no* material changes to our significant accounting policies disclosed in *Note *1* - Nature of Activities and Summary of Significant Accounting Policies* and other Notes to the Consolidated Financial Statements included in our Annual Report on Form *10*-K for the fiscal year ended *December 31, 2025.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *8*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of the Company's management, the unaudited interim consolidated condensed financial statements as of and for the *three* months ended *March 31, 2026* and *2025*, have been prepared on the same basis as the audited consolidated statements as of and for the year ended *December 31, 2025*, and reflect all adjustments, consisting primarily of normal recurring adjustments, necessary for the fair presentation of its statement of financial position, results of operations and cash flows. The results of operations for the *three* months ended *March 31, 2026*, are *not* necessarily indicative of the operating results for any subsequent quarter, for the full fiscal year, or any future periods.

In the *fourth* quarter of *2025* we adopted a policy to account for transferable PTCs by analogy to the grant model within International Accounting Standards *20* (*IAS20*), to recognize the credits when earned upon production and dispensing of eligible RNG and ethanol. We presented all *twelve* months of *2025* PTC earnings in the *fourth* quarter of *2025* as income separate from revenue in the Consolidated Condensed Statement of Operations and Comprehensive Loss. Starting in the *first* quarter of *2026,* PTCs are presented within Revenues.

***2.* Cash, Cash Equivalents, and Restricted Cash**

Restricted cash shown in the Consolidated Condensed Balance Sheets includes amounts set aside pursuant to the Aemetis Biogas *1* LLC Term Loan Agreement and the Aemetis Biogas *2* LLC Construction and Term Loan Agreement for financing reserves and construction contingencies. These loans are described further in *Note *5* Debt*.

The following table reconciles cash, cash equivalents, and restricted cash reported in the Consolidated Balance Sheet to the total of the same amounts shown in the statement of cash flows:

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **March 31, 2026** | **December 31, 2025** |
| Cash and cash equivalents | $4797 | $4894 |
| Restricted cash presented with other assets | 2068 | 2992 |
| Total cash, cash equivalents, and restricted cash shown in the statement of cash flows | $6865 | $7886 |

---

***3.* Inventories**

Inventories consist of the following:

---

| | | |
|:---|:---|:---|
|  | ***As of*** | ***As of*** |
|  | ***March 31, 2026*** | ***December 31, 2025*** |
| Raw materials | $6040 | $9593 |
| Work-in-progress | 1799 | 1402 |
| Finished goods | 2545 | 632 |
| Total inventories | $10384 | $11627 |

---

As of *March 31, 2026* , and *December 31, 2025* , we recognized a lower of cost or net realizable value adjustment of $107 thousand and $158 thousand, respectively, related to inventory.

***4.* Property, Plant and Equipment**

Property, plant and equipment consist of the following:

---

| | | |
|:---|:---|:---|
|  | ***As of*** | ***As of*** |
|  | ***March 31, 2026*** | ***December 31, 2025*** |
| Land | $8591 | $8616 |
| Plant and buildings | 200003 | 200008 |
| Furniture and fixtures | 2877 | 3036 |
| Machinery and equipment | 5351 | 5894 |
| Construction in progress | 62782 | 57043 |
| Property held for development | 15431 | 15431 |
| Finance lease right of use assets | 2776 | 2889 |
| Total gross property, plant & equipment | 297811 | 292917 |
| Less accumulated depreciation | (75068) | (73200) |
| Total net property, plant & equipment | $222743 | $219717 |

---

For the *three* months ended *March 31, 2026* and *2025*, interest capitalized in property, plant and equipment was $1.1 million and $1.0 million, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *9*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

Construction in progress includes biogas dairy digesters, mechanical vapor recompression at the Keyes Plant, the Riverbank sustainable aviation fuel and renewable diesel plant, and CCUS facilities. Property held for development is the partially completed plant in Goodland, Kansas (the "Goodland Plant"). Depreciation begins for each project when construction is complete and the project is placed into service, and is calculated using the straight-line method to allocate the depreciable amount over the estimated useful life of the applicable asset as follows:

---

| | | |
|:---|:---|:---|
|  | **Years** | **Years** |
| Plant and buildings |  | 20 - 30 |
| Machinery and equipment |  | 5 - 15 |
| Furniture and fixtures |  | 3 - 5 |

---

For the *three* months ended *March 31, 2026* and *2025*, we recorded depreciation expense of $2.5 million and $2.4 million, respectively.

***5.* Debt**

Debt consists of the following:

---

| | | |
|:---|:---|:---|
|  | ***March 31, 2026*** | ***December 31, 2025*** |
| Third Eye Capital term notes | $7277 | $7258 |
| Third Eye Capital revenue participation term notes | 12214 | 12185 |
| Third Eye Capital revolving credit facility | 39686 | 36368 |
| Third Eye Capital revolving notes Series B | 90164 | 85430 |
| Third Eye Capital acquisition term notes | 27007 | 26934 |
| Third Eye Capital Fuels Revolving Line | 52932 | 49230 |
| Third Eye Capital Carbon Revolving Line | 30881 | 29763 |
| Third Eye Capital short term promissory note | 2030 |  |
| Construction term loans | 48376 | 48690 |
| Cilion shareholder seller notes payable | 7518 | 7463 |
| Subordinated notes | 21598 | 21065 |
| EB-5 promissory notes | 39522 | 39409 |
| Working Capital loans | 3260 |  |
| Term loans on capital expenditures | 561 | 563 |
| Equipment financing | 39 | 45 |
| Short term construction funding | 21615 | 17361 |
| Total debt | 404680 | 381764 |
| Less current portion of debt | 342630 | 317869 |
| Total long term debt | $62050 | $63895 |

---

***Third Eye Capital Keyes Notes.*** On *July 6, 2012,* Aemetis, Inc., Aemetis Advanced Fuels Keyes, Inc. ("AAFK"), and Aemetis Facility Keyes, Inc. ("AFK") entered into an Amended and Restated Note Purchase Agreement (the "Note Purchase Agreement") with Third Eye Capital Corporation ("Third Eye Capital"). Pursuant to the Note Purchase Agreement, Third Eye Capital, as administrative agent on behalf of several noteholders, extended credit in the form of (i) senior secured term loans in an aggregate principal amount of approximately $7.2 million to replace existing notes held by Third Eye Capital (the "Term Notes"); (ii) senior secured revolving loans in an aggregate principal amount of $18.0 million (the "Revolving Credit Facility"); (iii) senior secured term loans in the principal amount of $10.0 million to convert the prior revenue participation agreement to notes (the "Revenue Participation Term Notes"); and (iv) senior secured term loans in an aggregate principal amount of $15.0 million (the "Acquisition Term Notes") used to fund the cash portion of the acquisition of Cilion, Inc. On *May 16, 2023,* we entered into a new Revolving Notes Series B agreement with Third Eye Capital related to certain existing principal under the Revolving Credit Facility and for subsequent principal increases. The Term Notes, Revolving Credit Facility, Revolving Notes Series B, Revenue Participation Term Notes, and Acquisition Term Notes are referred to herein collectively as the "Third Eye Capital Keyes Notes." The Third Eye Capital Keyes Notes have been amended several times, and the current key terms are as follows:

A. *Term Notes*. The Term Notes accrue interest at 14% per annum and are due on demand. As of *March 31, 2026*, we had $7.3 million in principal, interest and fees outstanding under the Term Notes.

B. *Revolving Credit Facility*. The Revolving Credit Facility accrues interest at prime rate plus 13.75% (20.50% as of *March 31, 2026*) payable monthly in arrears and is due on demand. As of *March 31, 2026*, we had $39.7 million in principal, interest and waiver fees outstanding under the Revolving Credit Facility.

C. *Revolving Notes Series B*. The Revolving Notes Series B accrue interest at prime rate plus 13.75% (20.50% as of *March 31, 2026*) payable monthly in arrears and is due on demand. As of *March 31, 2026*, we had $90.2 million in principal, interest and waiver fees outstanding under the Revolving Notes Series B.

---

| | |
|:---|:---|
| D.  | *Revenue Participation Term Notes*. The Revenue Participation Term Notes accrue interest at 5% per annum and are due on demand. As of *March 31, 2026*, we had $12.2 million in principal and interest outstanding under the Revenue Participation Term Notes. |

---

E. *Acquisition Term Notes*. The Acquisition Term Notes accrue interest at prime rate plus 10.75% (17.50% as of *March 31, 2026*) and are due on demand. As of *March 31, 2026*, we had $19.5 million in principal, interest, and a $7.5 million in redemption fee outstanding under the Acquisition Term Notes. 

F. *Short term promissory note.* In *March 2026,* the Company borrowed $2.0 million from Third Eye Capital and issued a promissory note accruing interest at 20.5% per annum, maturing on *April 30, 2026.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *10*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

The Third Eye Capital Keyes Notes contain various covenants, including but *not* limited to, debt to plant value ratio, minimum production requirements, and restrictions on capital expenditures. As of *March 31, 2026,* we obtained a waiver for the violation of debt to plant value ratio covenant. The terms of the Notes allow the lender to call the debt in the event of a default that could reasonably be expected to have a material adverse effect on the Company, such as any change in the business, operations, or financial condition. The notes allow interest to be added to the outstanding principal balance. The notes are secured by *first* priority liens on all real and personal property of, assignment of proceeds from all government grants, and guarantees from our North American subsidiaries except for Aemetis Biogas LLC and its subsidiaries and contain cross-collateral and cross-default provisions. McAfee Capital, LLC ("McAfee Capital"), owned by Eric McAfee, the Company's Chairman and CEO, provided a guaranty of payment and performance secured by all Company shares owned by McAfee Capital and additional assets, and Mr. McAfee has also provided a personal guaranty of up to $10 million plus a pledge of his ownership interest in several personal assets.

***Third Eye Capital Fuels and Carbon Credit Facilities.*** On *March 2, 2022,* Goodland Advanced Fuels, Inc. ("GAFI") and Aemetis Carbon Capture, Inc. ("ACCI") entered into an Amended and Restated Credit Agreement ("Credit Agreement") with Third Eye Capital, as administrative agent and collateral agent, and the lender parties thereto that provides *two* credit lines, *one* with GAFI (the "Fuels Revolving Line") and a *second* with ACCI (the "Carbon Revolving Line"). Loans received under the Fuels Revolving Line are due on demand. They accrue interest per annum at a rate equal to the greater of (i) the prime rate plus 11.00% and (ii) *fifteen* percent (15.0%) (17.75% as of *March 31, 2026*). Loans received under the Carbon Revolving Line are due on demand, and accrue interest per annum at a rate equal to the greater of (i) the prime rate plus 9.00% and (ii) *thirteen* percent (13.0%) (15.75% as of *March 31, 2026*). The Credit Agreement contains several affirmative and negative covenants, and loans under the Credit Agreement are secured by *first* priority liens on all real and personal property of and guarantees from the Company's U.S. subsidiaries except for Aemetis Biogas LLC (and its subsidiaries). As of *March 31, 2026* and *December 31, 2025*, GAFI had principal and interest outstanding of $52.9 million and $49.2 million, respectively, classified as current debt. As of *March 31, 2026*, ACCI had principal and interest outstanding of $30.9 million classified as current debt. As of *December 31, 2025*, ACCI had principal and interest outstanding of $30.0 million classified as current debt, and $0.2 million in unamortized debt issuance costs.

***Cilion Purchase Obligation***. In connection with the merger between Aemetis Facility Keyes, Inc. and Cilion, Inc. ("Cilion") on *July 6, 2012,* we incurred a $5.0 million payment obligation to Cilion shareholders as merger compensation. The liability accrues interest at 3% per annum. As of both *March 31, 2026* and *2025,* we had $7.5 million in principal and interest outstanding under the Cilion purchase obligation, classified as current debt.

***Subordinated Notes***. In *2012* and *2013,* AAFK entered into Note and Warrant Purchase Agreements with *two* accredited investors pursuant to which it issued $3.4 million in notes to the investors ("Subordinated Notes"). The Subordinated Notes mature every *six* months, and the current maturity date is *June 30, 2026.* Upon maturity, the Subordinated Notes are renewable at our election for *six*-month periods with a fee of 10% of the original note amount added to the balance outstanding plus issuance of warrants exercisable for the purchase of 113 thousand shares of Aemetis, Inc. common stock at $0.01 per share with a two-year term. Interest accrues at 10% per annum and is due at maturity. Neither AAFK nor Aemetis *may* make any principal payments under the Subordinated Notes until all AAFK debts to Third Eye Capital are paid in full. As of *March 31, 2026*, and *December 31, 2025*, AAFK had, in aggregate, $21.9 million and $21.6 million in principal and interest outstanding, respectively, under the Subordinated Notes. As of *March 31, 2026* and *December 31, 2025*, AAFK had $0.3 million and $0.5 million in unamortized debt issuance costs related to the subordinated notes, respectively.

***EB-*5* Promissory Notes***. EB-*5* is a U.S. government program authorized by the Immigration and Nationality Act that is designed to foster employment-based visa preference for immigrant investors to encourage the flow of capital into the U.S. economy and to promote employment of U.S. workers. The Company's subsidiary AE Advanced Fuels, Inc. ("AEAF") entered into a Note Purchase Agreement dated *March 4, 2011 (*as further amended on *January 19, 2012* and *July 24, 2012)* with Advanced BioEnergy, LP, a California limited partnership authorized by U.S. Citizenship and Immigration Services as a Regional Center to receive EB-*5* investments, for the issuance of up to *72* subordinated convertible promissory notes (the "EB-*5* Notes") bearing interest at *2* to *3%.* The EB-*5* Notes are convertible into Aemetis, Inc. common stock at a conversion price of $30 per share. Advanced BioEnergy, LP received equity investments from foreign investors, and then Advanced BioEnergy, LP used the invested equity to make loans to AEAF. The EB-*5* Notes are subordinated to the Company's senior secured debt to Third Eye Capital. On *February 27, 2019,* Advanced BioEnergy, LP, and AEAF entered into an Amendment to the EB-*5* Notes that modified the stated maturity dates of the EB-*5* Notes to provide automatic *six*-month extensions as long as the Advanced BioEnergy, LP investors' immigration processes are in progress. Accordingly, notes derived from Advanced BioEnergy, LP equity provided by investors pending green card approval have been recognized as long-term debt while notes derived from Advanced BioEnergy, LP equity provided by investors who have obtained green card approval have been classified as current debt. As of *March 31, 2026*, and *December 31, 2025*, $35.0 million and $34.9 million was outstanding, respectively, on the EB-*5* Notes.

In *2016,* the Company launched its EB-*5* Phase II funding (the "EB-*5* Phase II Funding") and entered into certain Note Purchase Agreements with Advanced BioEnergy II, LP, a California limited partnership authorized to receive EB-*5* equity funding investments. The Company's subsidiary Aemetis Advanced Products Keyes, Inc. received $4 million in loan funds from Advanced BioEnergy II, LP from *2018* to *2019.* As of both *March 31, 2026*, and *December 31, 2025*, $4.5 million was outstanding on the notes under the EB-*5* Phase II funding, respectively.

***India Biodiesel Secured and Unsecured Loans.*** On *January 7, 2026,* the Company's subsidiary Universal Biofuels Private Limited ("UBPL") entered into a secured loan agreement with a trade partner in an amount *not* to exceed $3.2 million that is secured by the fixed and currents assets of the Kakinada Plant. On *February 8, 2026,* UBPL entered into a short-term loan agreement with a different trade partner in an amount *not* to exceed $1.1 million. Each loan bears interest at 18% that is payable monthly. The draws under each loan must be repaid within twelve months of the draw date. During the *three* months ended *March 31, 2026*, UBPL received a total of $4.0 million in draws and repaid the principal in full under these agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *11*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

UBPL maintains a factoring arrangement to leverage certain trade receivables and receive short-term funding from a *third*-party financial institution. UBPL retains the risk of nonpayment on the transferred receivables, so the arrangement does *not* meet the criteria for sale accounting under ASC *860,* and we account for the funding as secured borrowing. Under this arrangement, UBPL receives cash advances that are recorded as debt, and the funds received are net of 8.1% interest that is recorded as interest expense. UBPL retains the accounts receivable balances in its balance sheet. During the *three* months ended *March 31, 2026*, UBPL received a total of $6.9 million in draws and repaid $3.6 million under this agreement.

As of *March 31, 2026*, and *December 31, 2025*, UBPL's outstanding balances under all loan agreements totaled $3.3 million and $0.0 million, respectively.

***Aemetis Biogas *1* LLC Term Loan.*** On *October 4, 2022,* Aemetis Biogas *1* LLC (*"AB1"*) entered into a Construction Loan Agreement (*"AB1* Construction Loan") pursuant to which the lender made available an aggregate principal amount of $25 million. Effective *December 22, 2023,* the *AB1* Construction Loan was refinanced and replaced with a term loan (*"AB1* Term Loan") that is secured by all personal and real property of *AB1.* It bears interest at a rate of 9.25% per annum, to be adjusted every *five* years to equal the *five*-year Treasury Constant Maturity Rate, as published by the Board of Governors of the Federal Reserve System as of the adjustment date, plus 5.00% or (ii) the index floor. Other material terms of the loan include: (i) monthly payments of interest only beginning *January 22, 2024, (*ii) equal monthly payments of principal and interest beginning *January 22, 2025,* and (iii) a maturity date of *December 22, 2042,* at which time the unpaid principal and interest are due and payable. The *AB1* Term Loan contains certain financial covenants to be measured as of the last day of each fiscal year beginning fiscal year end *2025,* and annually for the term of the loan. The *AB1* Term Loan also contains other affirmative and negative covenants, representations and warranties, and events of default customary for loan agreements of this nature. As of *March 31, 2026*, and *December 31, 2025*, *AB1* had $24.3 million and $24.5 million outstanding, respectively, under the *AB1* Term Loan.

***Aemetis Biogas *2* LLC Construction and Term Loan.*** On *July 28, 2023,* Aemetis Biogas *2* LLC (*"AB2"*) entered into a Construction and Term Loan Agreement (*"AB2* Loan"), pursuant to which the lender made available an aggregate principal amount of $25 million. The loan is secured by all personal and real property of *AB2.* The loan bears interest at a rate of 8.75% per annum, to be adjusted every *five* years to equal the *five*-year Treasury Constant Maturity Rate, as published by the Board of Governors of the Federal Reserve System as of the adjustment date, plus 5.00%. Other material terms of the *AB2* Loan include: (i) monthly payments of interest only beginning *August 15, 2023, (*ii) equal monthly payments of principal and interest beginning *August 15, 2025,* and (iii) a maturity date of *July 28, 2043,* at which time the unpaid principal and interest are due and payable. The *AB2* Loan contains certain financial covenants to be measured as of the last day of each fiscal year beginning fiscal year end *2025,* and annually for the term of the loan. The *AB2* Loan also contains other affirmative and negative covenants, representations and warranties, and events of default customary for loan agreements of this nature. As of *March 31, 2026*, and *December 31, 2025*, *AB2* had $24.8 million and $25.0 million outstanding, respectively, and unamortized discount issuance costs of $0.8 million and for both periods, under the *AB2* Loan.

***Term loans on equipment financing.*** In order to purchase production equipment in *2025,* AAFK entered into a financing agreement totaling $51 thousand with interest payable at 7.49% per year. As of *March 31, 2026* and *December 31, 2025*, AAFK had outstanding balances under this agreement of $39 thousand and $45 thousand.

***Term loans on capital expenditures*.** In connection with the acquisition of a vehicle in *2021,* Aemetis Biogas Services ("ABS") entered into a financing agreement totaling $54.5 thousand with interest payable at 6.59% per year. As of *March 31, 2026*, and *December 31, 2025*, ABS had outstanding balances under this agreement of $10.6 thousand and $12.9 thousand.

In connection with its acquisition of real property in *November 2024,* the Company's subsidiary Aemetis RNG Fuels *1* LLC (*"RNG1"*) entered into *two* installment note agreements with private lenders totaling $840 thousand with interest payable monthly at 11.99% per year. As of both *March 31, 2026*, and *December 31, 2025*, *RNG1* had outstanding balances under these agreements totaling $550 thousand.

***Short term construction funding.*** In connection with the construction of the Mechanical Vapor Recompression ("MVR") system at the Keyes plant, AAFK entered into a construction agreement whereby it will pay the contractor amounts owed under the construction agreement *60* days following completion of the project. The unpaid costs accrue interest at 7.75% until payment. As of *March 31, 2026,* the balance owed was $21.6 million, classified as short-term borrowings.

***Maturity Date Schedule***

The following table shows scheduled repayments for the Company's debt obligations by year:

---

| | |
|:---|:---|
| **Twelve Months ended March 31,** | ***Debt Repayments*** |
| 2027 | $342630 |
| 2028 | 15950 |
| 2029 | 1309 |
| 2030 | 1435 |
| 2031 | 1572 |
| Thereafter | 42535 |
| Total debt | 405431 |
| Debt issuance costs | (751) |
| Total debt, net of debt issuance costs | $404680 |

---

 ***6.* Basic and Diluted Net Loss Per Share**

Basic net loss per share is computed by dividing the income or loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the dilution of common stock equivalents such as options, convertible debt, and warrants to the extent the impact is dilutive. The following table shows the number of potentially dilutive shares excluded from the diluted net loss per share calculation as of *March 31, 2026* and *2025* because their effect would have been anti-dilutive:

---

| | | |
|:---|:---|:---|
|  | ***As of*** | ***As of*** |
|  | ***March 31, 2026*** | ***March 31, 2025*** |
| Common stock options and warrants | &nbsp;&nbsp;&nbsp;10900 | &nbsp;&nbsp;&nbsp;9434 |
| Debt with conversion feature at $30 per share of common stock | &nbsp;&nbsp;&nbsp;1167 | &nbsp;&nbsp;&nbsp;1156 |
| Total number of potentially dilutive shares | &nbsp;&nbsp;&nbsp;12067 | &nbsp;&nbsp;&nbsp;10590 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *12*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

***7.* Revenue and Accounts Receivable**

***California Ethanol Revenues:*** We sell our ethanol segment products to J.D. Heiskell, which sells them to *third* parties designated by us. We record revenue when we transfer ethanol into our storage tank, which is leased to J.D. Heiskell, and when product is loaded into shipping trucks for products other than ethanol. We also buy our corn feedstock from J.D. Heiskell. Transaction prices for ethanol sales and corn purchases are based on daily market prices. We invoice J.D. Heiskell each business day for the net balance between ethanol and other product sales and our corn purchases, and J.D. Heiskell pays on the next business day. In the *first* quarter of *2026,* we recognized Section *45Z* PTC income upon production of eligible ethanol. The following table lists the California Ethanol segment revenues:

---

| | | |
|:---|:---|:---|
|  | ***For the three months ended March 31,*** | ***For the three months ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Ethanol sales | $27122 | $28059 |
| Wet distiller's grains sales | 7680 | 8001 |
| Other sales | 1428 | 1688 |
| Total revenue from contracts with customers | 36230 | 37748 |
| PTC income | 2595 |  |
| Total revenue | $38825 | $37748 |

---

***California Dairy Renewable Natural Gas Revenues:*** Our renewable natural gas ("RNG") production facilities as of *March 31, 2026*, include *twelve* anaerobic digesters that produce biogas from manure waste received from *fifteen* dairies, a *36*-mile biogas collection pipeline leading from the dairy digesters to a central upgrading hub that produces RNG, and an interconnect to inject the RNG into the utility natural gas pipeline for delivery to customers for use as transportation fuel. We also generate sellable credits under the federal Renewable Fuel Standard (referred to as *"D3* RINs") and the California Low Carbon Fuel Standard ("LCFS"), as well as other tax credit programs. We recognize revenue from natural gas sales when we inject the RNG into the utility pipeline and we recognize revenue from sales of *D3* RINs and LCFS credits when we sell the credits. We recognize Section *45Z* PTC income upon dispensing of eligible RNG. The following table lists the RNG segment revenues:

---

| | | |
|:---|:---|:---|
|  | ***For the three months ended March 31,*** | ***For the three months ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Gas sales | $217 | $259 |
| LCFS credit sales | 1664 | 1160 |
| RIN sales | 1931 | 1024 |
| Total revenue from contracts with customers | 3812 | 2443 |
| PTC income | 1443 |  |
| Total revenue | $5255 | $2443 |

---

***India Biodiesel Revenues:*** We sell biodiesel to the government-owned India Oil Market Companies pursuant to tender offers, and we sell refined glycerin to private parties. We also occasionally sell feedstock based on market conditions. The following table shows sales in our India Biodiesel segment by product category:

---

| | | |
|:---|:---|:---|
|  | ***For the three months ended March 31,*** | ***For the three months ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Biodiesel sales | $9533 | $- |
| Other sales | 1006 | 2695 |
| Total revenue | $10539 | $2695 |

---

Across all segments, revenue is recognized at the point in time when performance obligations have been met. Accounts receivable for all segments represent invoicing with varying payment terms, but with *no* variable consideration or financing. The opening balance of accounts receivable for all segments as of *January 1, 2025,* was $1.8 million, respectively, and the closing balance as of *March 31, 2026* and *December 31, 2025*, were $6.6 million and $0.5 million, respectively. Allowance for credit losses on trade receivables as of *March 31, 2026*, and *December 31, 2025*, for all segments was $457.4 thousand and $385.0 thousand, respectively. There were no liabilities for unearned revenue for any segments as of *March 31, 2026*.

***8.* Leases**

We are a party to operating leases for our corporate office in Cupertino, modular offices, land leases and laboratory facilities. We have also entered into several finance leases for mobile equipment and for the Riverbank Industrial Complex. These finance leases have a purchase option at the end of the term that we are reasonably certain we will exercise, so the leases are classified as finance leases. All of our leases aside from our land leases have remaining terms of one year to 13 years; the land leases have remaining terms over 20 years. We apply an accounting policy election to keep leases with an initial term of *12* months or less off the balance sheet, and recognize those lease payments in the Consolidated Statements of Operations as we incur the expenses.

We evaluate leases in accordance with ASC **842* – *Lease Accounting*. When discount rates implicit in leases cannot be readily determined, we use the applicable incremental borrowing rate at lease commencement to perform lease classification tests on lease components and to measure lease liabilities and right of use ("ROU") assets. The incremental borrowing rate we use is based on weighted average baseline rates commensurate with our secured borrowing rate, over a similar term. At each reporting period when there is a new lease initiated, the rates established for that quarter are used.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *13*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

The components of lease expense are as follows:

---

| | | |
|:---|:---|:---|
|  | ***Three months ended March 31,*** | ***Three months ended March 31,*** |
|  | ***2026*** | ***2025*** |
| **Operating lease cost** |  |  |
| Operating lease expense | $180 | $190 |
| Short term lease expense | 103 | 45 |
| Variable lease expense | 44 | 23 |
| Total operating lease cost | $327 | $258 |
| **Finance lease cost** |  |  |
| Amortization of right-of-use assets | $23 | $30 |
| Interest on lease liabilities | 97 | 90 |
| Total finance lease cost | $120 | $120 |

---

Cash paid for amounts included in the measurement of lease liabilities:

---

| | | |
|:---|:---|:---|
|  | ***Three months ended March 31,*** | ***Three months ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Operating cash flows used in operating leases | $175 | $186 |
| Operating cash flows used in finance leases | 97 | 90 |
| Financing cash flows used in finance leases |  | 9 |

---

Supplemental non-cash flow information related to ROU asset and lease liabilities was as follows for the *three* months ended *March 31, 2026* and *2025*:

---

| | | |
|:---|:---|:---|
|  | ***Three months ended March 31,*** | ***Three months ended March 31,*** |
|  | ***2026*** | ***2025*** |
| **Operating leases** |  |  |
| Accretion of the lease liability | $69 | $77 |
| Amortization of right-of-use assets | 111 | 113 |
| The weighted average remaining lease term and weighted average discount rate as of March 31, 2026 are as follows: |  |  |
| *Weighted Average Remaining Lease Term* | *Weighted Average Remaining Lease Term* |  |
| Operating leases (in years) | 11.8 | 8.0 |
| Finance leases (in years) | 11.0 | 11.9 |
| Weighted Average Discount Rate |  |  |
| Operating leases | 12.5% | 13.7% |
| Finance leases | 13.3% | 13.3% |

---

Supplemental balance sheet information related to leases is as follows:

---

| | | |
|:---|:---|:---|
|  | ***March 31, 2026*** | ***December 31, 2025*** |
| **Operating leases** |  |  |
| Operating lease right-of-use assets | $2145 | $2256 |
| Other current liability | 572 | 554 |
| Other long term liabilities | 1654 | 1778 |
| Total operating lease liabilities | 2226 | 2332 |
| **Finance leases** |  |  |
| Property and equipment, at cost | $2776 | $2889 |
| Accumulated depreciation | (370) | (460) |
| Property and equipment, net | 2406 | 2429 |
| Other current liability | 259 | 251 |
| Other long term liabilities | 2921 | 2832 |
| Total finance lease liabilities | 3180 | 3083 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *14*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

Maturities of operating and finance lease liabilities are as follows:

---

| | | |
|:---|:---|:---|
| Twelve months ended March 31, | ***Operating leases*** | ***Finance leases*** |
| 2027 | $803 | $145 |
| 2028 | 758 | 145 |
| 2029 | 216 | 145 |
| 2030 | 108 | 145 |
| 2031 | 110 | 145 |
| Thereafter | 2098 | 9815 |
| Total lease payments | 4093 | 10540 |
| Less imputed interest | (1867) | (7360) |
| Total lease liability | $2226 | $3180 |

---

We act as sublessor in certain leasing arrangements, primarily related to land and buildings. Fixed sublease payments received are recognized on a straight-line basis over the sublease term. Sublease income and head lease expense for these transactions are recognized on a net basis on the consolidated financial statements. Sublease income is recorded in the Selling, General and Administrative Expenses section of the Consolidated Condensed Statements of Operations and Comprehensive Loss.

The components of lease income are as follows for the *three* months ended *March 31, 2026* and *2025*, respectively:

---

| | | |
|:---|:---|:---|
|  | ***Three months ended March 31,*** | ***Three months ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Lease income | $606 | $683 |

---

Future lease commitments to be received as of *March 31, 2026*, are as follows:

---

| | |
|:---|:---|
| Twelve months ended March 31, |  |
| 2027 | $1757 |
| 2028 | 1635 |
| 2029 | 1621 |
| 2030 | 1380 |
| 2031 | 29 |
| Thereafter |  |
| Total future lease commitments | $6422 |

---

***9.* Stock Based Compensation**

 ***2019* Stock Plan***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Aemetis, Inc. Amended and Restated *2019* Stock Plan (the *"2019* Stock Plan") allows our Board of Directors or delegated Board committee to grant Incentive Stock Options, Non-Statutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, Performance Shares, and other stock or cash awards to employees, directors, and consultants. During the *three* months ended *March 31, 2026*, we issued stock options to employees exercisable for 1.8 million shares, and we issued 379 thousand shares of stock to members of our Board of Directors as compensation. The following table summarizes activity under the *2019* Stock Plan during the *three* months ending *March 31, 2026*:

---

| | | | |
|:---|:---|:---|:---|
|  | ***Shares Available for Grant*** | ***Number of Shares Outstanding*** | ***Weighted-Average Exercise Price*** |
| Balance as of December 31, 2025 | 81 | 8610 | 3.91 |
| Authorized | 2749 | *-* | *-* |
| Options Granted | (1828) | 1828 | 2.64 |
| Common Stock Granted | (379) | *-* | *-* |
| Exercised | *-* |  |  |
| Forfeited/expired | 23 | (23) | 2.85 |
| Balance as of March 31, 2026 | 646 | 10415 | $3.69 |

---

The options outstanding as of *March 31, 2026*, include vested rights to purchase 6.8 million shares and the remaining purchase rights are *not* yet vested.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *15*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

 ***Stock-based Compensation Expense***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation is accounted for in accordance with *ASC *718,* Compensation - Stock Compensation*, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, directors, and consultants based on estimated fair value on the grant date. We estimate the fair value using the Black-Scholes option pricing model and recognize that fair value as an expense over the vesting period of each grant using the straight-line method. The Black-Scholes valuation model for stock-based compensation expense requires us to make assumptions and judgments about the variables used in the calculation, including the expected term (the period of time that the options granted are expected to be outstanding), the volatility of our common stock, a risk-free interest rate, expected dividends, and expected forfeitures. We use the simplified calculation of expected term described in SEC Staff Accounting Bulletin Topic *14, Share-Based Payment*. Volatility is based on an average of the historical volatility of Aemetis, Inc. common stock during the period of time preceding the date of option issuance that matches the term of the option grant. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for the treasury maturity term corresponding with the expected life of the option. We use an expected dividend yield of zero, as we do *not* anticipate paying any dividends in the foreseeable future. Expected forfeitures are assumed to be *zero* due to the small number of plan participants. To the extent actual forfeitures occur, the difference is recorded as an adjustment in the scheduled expense during the period of the forfeiture.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The weighted average fair value calculations for the options granted during the *three* months ended *March 31, 2026* and *2025*, are based on the following assumptions:

---

| | | |
|:---|:---|:---|
|  | ***For the three months ended March 31,*** | ***For the three months ended March 31,*** |
| **Description** | ***2026*** | ***2025*** |
| Dividend-yield | *-*% | *-*% |
| Risk-free interest rate | 3.84% | 4.30% |
| Expected volatility | 111.15% | 113.50% |
| Expected life (years) | 5.81 | 5.81 |
| Market value per share on grant date | $2.64 | $2.73 |
| Fair value per option on grant date | $2.21 | $2.32 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During the *three* months ended *March 31, 2026* and *2025*, we recognized $1.7 million and $2.3 million of stock-based compensation expense. During these periods we granted 379 thousand and 369 thousand shares of common stock under the *2019* Stock Plan, respectively, with a fair value on date of grant of $2.64 and $2.73, respectively, per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As of *March 31, 2026*, we had $7.2 million of total unrecognized compensation expense for option issuances, which we will amortize over the remaining vesting period for each applicable grant, which has a weighted average of 2.32 years as of *March 31, 2026*.

***10.* Warrants to Purchase Common Stock**

On *December 31, 2025,* the maturity dates on *two* accredited investor's Subordinated Notes were extended to *June 30, 2026.* In connection with the extension, we granted the noteholders warrants exercisable for the purchase of 113 thousand shares of Aemetis, Inc. common stock with a term of two years and an exercise price of $0.01 per share. The warrants were fully exercised by the noteholders in *January 2026.*

The following table summarizes warrant activity during the *three* months ending *March 31, 2026*:

---

| | | | |
|:---|:---|:---|:---|
|  | ***Warrants Outstanding & Exercisable*** | ***Weighted - Average Exercise Price*** | ***Average Remaining Term in Years*** |
| Outstanding December 31, 2025 | 598 | $10.17 | 3.73 |
| Granted |  |  |  |
| Exercised | (113) | 0.01 |  |
| Outstanding March 31, 2026 | 485 | $12.55 | 3.89 |

---

All of the above outstanding warrants are fully vested and exercisable as of *March 31, 2026*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *16*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

***11.* Aemetis Biogas LLC** – **Series A Preferred Financing**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On *December 20, 2018,* Aemetis Biogas LLC ("ABGL") entered into a Series A Preferred Unit Purchase Agreement for the sale of Series A Preferred Units to Protair- *X* Americas, Inc., with Third Eye Capital acting as an agent. ABGL is authorized to issue 11,000,000 common units and 6,000,000 convertible, redeemable, secured, preferred membership units (the "Series A Preferred Units"). ABGL issued 6,000,000 common units to Aemetis, Inc. at a stated value of $5.00 per common unit, and 5,000,000 common units of ABGL are held in reserve as potential conversion units issuable to the Preferred Unit holder upon certain triggering events. From inception of the agreement through *2022,* ABGL issued 6,000,000 Series A Preferred Units in exchange for $30.0 million in funding, reduced by a redemption of 20,000 Series A Preferred Units for $0.3 million. The original Preferred Unit Purchase Agreement included requirements for preference payments and mandatory redemption, grant of a security interest to the Preferred Unit holder in all assets of ABGL and its subsidiaries in connection with the preference payments due under the agreement, and several operating covenants.

The Preferred Unit Purchase Agreement has been amended multiple times. In *February 2026,* ABGL entered into an agreement titled Eleventh Waiver and Amendment to Series A Preferred Unit Purchase Agreement ("PUPA Eleventh Amendment") with an effective date of *December 31, 2025,* that, among other provisions, extends the date by which ABGL is required to redeem all of the outstanding Series A Preferred Units to *April 30, 2026,* and changes the aggregate redemption price to $114.7 million, which reflects the payment in *December 2025* and includes a $2 million incremental fee for the PUPA Eleventh Amendment. The PUPA Eleventh Amendment further provides that if ABGL does *not* redeem the Series A Preferred Units by the redemption date, ABGL will enter into a credit agreement with Protair-*X* and Third Eye Capital effective as of *May 1, 2026,* and maturing *May 1, 2027,* as shown in the form attached to the PUPA Eleventh Amendment, and specifies that entry into such credit agreement will satisfy the obligation to redeem the Series A Preferred Units. The credit agreement would bear an interest rate equal to the greater of (i) prime rate plus 10.0% and (ii) 16.0%. We evaluated this and prior similar amendments in accordance with ASC *470* "Debt" and applied troubled debt restructuring accounting, resulting in *no* gain or loss from the execution of the particular amendment. In addition, consistent with ASC *470*-*60,* we accreted the amount of principal and interest due using the effective interest method from the starting liability on the effective date of the amendment to the amount that would be due as of the maturity date of the credit agreement. Following this methodology, we recorded Series A Preferred Unit liabilities of $128.6 million and $126.9 million as long-term liabilities as of *March 31, 2026*, and *December 31, 2025*, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See *Note *15* Subsequent Events* for details regarding the Twelfth Waiver and Amendment to Series A Preferred Unit Purchase Agreement ("PUPA Twelfth Amendment").

&nbsp;&nbsp;&nbsp;&nbsp; *Variable interest entity assessment*

After consideration of ABGL's operations and the above agreement in *2018,* we concluded that ABGL did *not* have enough equity to finance its activities without additional financial support. ABGL is capitalized with Series A Preferred Units that are recorded as liabilities under U.S. GAAP. Hence, we concluded that ABGL is a VIE. Through our ownership interest in all of the outstanding common units of ABGL, our current ability to control the board of directors, the management fee paid to Aemetis, and control of subordinated financing decisions, Aemetis has been determined to be the primary beneficiary and accordingly, the assets, liabilities, and operations of ABGL are consolidated into those of the Company. ABGL's total assets as of *March 31, 2026*, were $113.0 million which serve as collateral for the obligations of ABGL to the holders of Series A Preferred Units.

***12.* Agreements**

***J.D. Heiskell Working Capital Agreements**.* Pursuant to a Corn Procurement and Working Capital Agreement with J.D. Heiskell, AAFK procures whole yellow corn from J.D. Heiskell. AAFK has the ability to obtain grain from other sources subject to certain conditions; however, in the past all AAFK grain purchases have been from J.D. Heiskell. Title to and risk of loss of the corn pass to AAFK when the corn is deposited into the Keyes Plant weigh bin. Pursuant to a separate agreement entered in *May 2023,* J.D. Heiskell also purchases all of our ethanol, WDG, corn oil, and CDS and sells them to marketing companies designated by us. We have designated Murex to purchase and market ethanol and A.L. Gilbert to purchase and market WDG and corn oil. Our relationships with J.D. Heiskell, Murex, and A.L. Gilbert are well established, and we believe that the relationships are beneficial to all parties involved in utilizing the distribution logistics, reaching a widespread customer base, managing inventory, and providing working capital relationships.

The following table summarizes the J.D. Heiskell purchase and sales activity during the *three* months ended *March 31, 2026* and *2025*:

---

| | | |
|:---|:---|:---|
|  | ***For the three months ended March 31,*** | ***For the three months ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Ethanol sales | $27122 | $28059 |
| Wet distiller's grains sales | 7680 | 8001 |
| Corn oil sales | 1257 | 1454 |
| CDS sales | 5 | 9 |
| Corn purchases | (28319) | (31354) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***March 31, 2026*** | ***March 31, 2026*** | ***December 31, 2025*** | ***December 31, 2025*** |
| Accounts receivable |  | 166 |  | 27 |

---

The agreements with J.D. Heiskell, Murex, and A.L. Gilbert include marketing and transportation services. For the *three* months ended *March 31, 2026* and *2025*, we expensed marketing costs of $0.6 million and $0.6 million, respectively, in connection with the marketing arrangements and these costs are included in Selling, General and Administrative Expenses. For the *three* months ended *March 31, 2026*, we expensed transportation costs of $1.0 million related to sales of ethanol and $1.3 million related to sales of WDG. For the *three* months ended *March 31, 2025*, we expensed $1.2 million related to sales of ethanol and $1.4 million related to sales of WDG. Transportation costs are included in costs of goods sold.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *17*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

***Supply Trade Agreement.*** On *July 1, 2022,* UBPL entered into an operating agreement with Gemini Edibles and Fats India Private Limited ("Gemini") pursuant to which Gemini supplies UBPL with feedstock up to a credit limit of $12.7 million and has a collateral interest in inventories, current assets, and fixed assets of UBPL. If UBPL fails to pay an invoice within the *ten*-day credit period, the outstanding balance bears interest at 18%. The agreement is effective through *July 2026.* As of *March 31, 2026*, and *December 31, 2025*, UBPL had $0 outstanding, respectively, under this agreement.

***Forward Sale Commitments.*** As of *March 31, 2026*, we have no forward sale commitments.

***Natural Gas Purchase Agreement.*** As of *March 31, 2026*, we have a forward purchase agreement in place to buy approximately 3,700 MMBtu of natural gas per day at fixed prices between $1.55 and $3.175 per MMBtu through *September 2026.* We have elected to apply the *normal purchases and normal sales scope exception under ASC *815* "Derivatives and Hedging,"* hence the natural gas purchased under this agreement is accounted for and included as cost of goods sold in our financial statements.

***13.* Segment Information**

We recognize three reportable segments: "California Ethanol," "California Dairy Renewable Natural Gas," and "India Biodiesel."

The "California Ethanol" segment includes our 65 million gallon per year ethanol plant in Keyes, California, and the adjacent land leased to upgrade our CO₂ production to commercial quality.

The "California Dairy Renewable Natural Gas" segment includes the production and sale of Renewable Natural Gas ("RNG") and associated environmental attributes, consisting of anaerobic digesters located at dairies, a *36*-mile biogas collection pipeline, a biogas upgrading hub that produces RNG from the biogas, a pipeline interconnect, and ongoing construction of additional digesters.

The "India Biodiesel" segment includes our 80 million gallon per year biodiesel production plant in Kakinada, India, and administrative offices in Hyderabad, India.

We have additional operating segments that were determined *not* to be separately reportable segments, including our key projects under development which consist of a sustainable aviation fuel and renewable diesel production in Riverbank and Carbon Capture and Underground Sequestration ("CCUS") wells in California. Additionally, the Goodland Plant, our Riverbank Industrial Complex management, and corporate expenses are included in the "All Other" category.

The following tables summarize financial information by reportable segment for the *three* months ended *March 31, 2026* and *2025*:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***For the three months ended March 31, 2026*** | ***For the three months ended March 31, 2026*** | ***For the three months ended March 31, 2026*** | ***For the three months ended March 31, 2026*** | ***For the three months ended March 31, 2026*** |
|  | ***California Ethanol*** | ***California Dairy Renewable Natural Gas*** | ***India Biodiesel*** | ***All Other*** | ***Total*** |
| Revenues | $38825 | $5255 | $10539 | $- | $54619 |
| Gross profit (loss) | 572 | 2074 | 110 |  | 2756 |
| Net Loss | (9704) | (2122) | (459) | (9428) | (21713) |
| Interest and debt amortization expense | 8964 | 1154 | 118 | 4138 | 14374 |
| Depreciation and amortization | 1056 | 1219 | 189 | 71 | 2535 |
| Accretion and other expenses of Series A preferred units |  | 1613 |  |  | 1613 |
| Bad debt expense | 72 |  |  | 204 | 276 |
| Income tax expense/(benefit) |  | 10 | (155) | 14 | (131) |
| Loss on sale of assets |  |  | 2 |  | 2 |
| Stock-based compensation expense |  |  |  | 1704 | 1704 |
| Stock issued for services |  |  |  | 50 | 50 |
| EBITDA | 388 | 1874 | (305) | (3247) | (1290) |
| Capital expenditures | 3354 | 3152 | 11 | 31 | 6548 |
| Total assets as of March 31, 2026 | 76489 | 113049 | 24855 | 55936 | 270329 |
| Allocation of corporate overhead expense to segments | 3443 | 3874 | 430 | (7747) |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *18*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***For the three months ended March 31, 2025*** | ***For the three months ended March 31, 2025*** | ***For the three months ended March 31, 2025*** | ***For the three months ended March 31, 2025*** | ***For the three months ended March 31, 2025*** |
|  | ***California Ethanol*** | ***California Dairy Renewable Natural Gas*** | ***India Biodiesel*** | ***All Other*** | ***Total*** |
| Revenues | $37748 | $2443 | $2695 | $- | $42886 |
| Gross profit | (4938) | 305 | (447) |  | (5080) |
| Net income (loss) | (14910) | 1762 | (1712) | (9669) | (24529) |
| Interest expense including amortization of debt fees | 8461 | 948 | 456 | 3828 | 13693 |
| Accretion and other expenses of Series A preferred units |  | 2279 |  |  | 2279 |
| Monetized investment tax credits |  | (7075) |  |  | (7075) |
| Income tax expense |  | 80 | 201 | 11 | 292 |
| Depreciation | 1101 | 1009 | 183 | 64 | 2357 |
| Stock-based compensation expense |  |  |  | 2308 | 2308 |
| Other amortization | 12 |  |  |  | 12 |
| EBITDA | (5336) | (997) | (872) | (3458) | (10663) |
| Capital expenditures | 43 | 1257 | 379 | 146 | 1825 |
| Total assets as of December 31, 2025 | 71861 | 113643 | 21486 | 52851 | 259841 |
| Allocation of corporate overhead expense to segments | 2684 | 4474 | 895 | (8053) |  |

---

&nbsp;&nbsp;&nbsp;&nbsp; *California Ethanol:* J.D. Heiskell accounted for over *90%* of all Ethanol Segment sales for the *three* months ended *March 31, 2026* and *2025*.

&nbsp;&nbsp;&nbsp;&nbsp; *California Dairy Renewable Natural Gas:* Sales of RNG during the *three* months ended *March 31, 2026* and *2025*, were to a single customer. We sold *D3* RINs and LCFS credits to *two* other customers.

&nbsp;&nbsp;&nbsp;&nbsp; *India Biodiesel:* For the *three* months ended *March 31, 2026* , three customers accounted for 22%, 26%, and 42% of our India Biodiesel segment's revenues. For the *three* months ended *March 31, 2025*, two customers accounted for 18% and 73% of the segment's revenues.

***14.* Related Party Transactions**

As of *March 31, 2026*, the Company had amounts payable totaling $1.7 million to Eric McAfee, our Chairman and Chief Executive Officer, and McAfee Capital LLC, an entity owned by Mr. McAfee. These amounts consist of accrued compensation and related amounts under employment agreements and bonus awards, expense reimbursements, and guarantee fees associated with guarantees provided by Mr. McAfee and McAfee Capital in connection with the Company's indebtedness to Third Eye Capital.

In addition, as of *March 31, 2026,* the Company had amounts payable totaling $0.9 million to other members of management related to awarded but unpaid bonus compensation.

***15.* Subsequent Events**

On *May 5, 2026*, Aemetis Biogas LLC ("ABGL") entered into an agreement titled Twelfth Waiver and Amendment to Series A Preferred Unit Purchase Agreement ("PUPA Twelfth Amendment") with an effective date of *April 30, 2026,* that requires, among other provisions, ABGL to either (i) redeem all outstanding Series A Preferred Units by *August 31, 2026,* for an aggregate redemption price of $116.7 million or (ii) to enter into a credit agreement in the form attached to the PUPA Twelfth Amendment. The PUPA Agreement is described further in *Note *11* Aemetis Biogas LLC* - *Series A Preferred Financing*.

***16.* Liquidity and Going Concern**

The accompanying financial statements have been prepared contemplating the realization of assets and satisfaction of liabilities in the normal course of business. This approach to presentation is qualified by the following additional descriptions of our financial position.

***Debt***

We have a substantial amount of accumulated debt, and our senior lender has a security interest in substantially all of our assets. We have been reliant on our senior secured lender to provide extensions to the maturity dates of its debt facilities and have been required to remit substantially all excess cash from tax credit sales as payments of that debt, in addition to other periodic payments. In order to meet our obligations during the next *twelve* months, we will need to refinance debt with our senior lender for amounts that are due on demand in the next *twelve* months or receive its continued cooperation.

***Operational Cash Flows***

We do *not* currently generate positive cash flow from our consolidated operations. We are reliant on obtaining additional liquidity to satisfy our operating obligations for the next *twelve* months. We are pursuing the following strategies to improve liquidity:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *19*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

<u>California Ethanol</u>

*Optimize Operations*. We plan to continue to operate the Keyes Plant and to optimize operating parameters and purchase contracts based on market conditions.

*Reduce Natural Gas Use and Reduce Ethanol Carbon Intensity*. We are constructing a Mechanical Vapor Recompression ("MVR") system that is expected to significantly reduce the Keyes Plant's natural gas consumption and lower the carbon intensity of the ethanol produced at the Keyes Plant. This will reduce overall fuel costs and volatility and increase income from LCFS credits and Section *45Z* production tax credits ("PTCs"). The MVR system is expected to become operational in *2026.*

*Monetize New Section *45Z* Tax Credits*. The Keyes Plant started earning Section *45Z* PTCs effective *January 1, 2025,* and we are in the process of monetizing the credits earned during *2025* and *2026.* The recent federal tax and budget legislation referred to as the "One Big Beautiful Bill" that was enacted in *July 2025* contains provisions that are expected to increase our future income from Section *45Z* PTCs for ethanol production, including an increase in the credit amount earned for each gallon of ethanol we produce and an extension of the term of the credits to a total of *five* years.

*Evaluate New Technologies*. We continue to evaluate other opportunities to improve the Keyes Plant's financial performance by adopting new technologies or process changes that further improve energy efficiency, decrease feedstock costs, increase coproduct yields, and create other margin enhancements.

<u>California Renewable Natural Gas</u>

*Operate Existing Digesters.* As of *March 31, 2026,* the RNG segment operates *twelve* anaerobic digesters that produce biogas from manure waste received from *fifteen* dairies.

*Construct New Digesters*. We plan to continue to build new dairy digesters that increase cash flow from operations as allowed by capital availability. We have agreements with over *fifty* dairies and expect the next set of digesters to begin producing biogas in the *third* quarter of *2026.* We are seeking new loans and other forms of financing from a variety of sources to facilitate additional digester construction.

*Increase LCFS Credit Revenue*. The California Air Resource Board ("CARB") has approved provisional pathways for the RNG produced from *seven* of our operating dairy digesters. Dairies with approved provisional LCFS pathways generate more LCFS credits than dairies with temporary pathways. We generate LCFS credits under lower temporary pathways at *five* operating digesters that have applications for provisional pathways pending with CARB. In addition, CARB's recently approved amendments to the LCFS regulation that became effective *July 1, 2025,* are expected to reduce the oversupply of LCFS credits and lead to higher LCFS credit prices in the future.

*Monetize New Section *45Z* Tax Credits*. Our RNG production started earning Section *45Z* production tax credits effective *January 1, 2025.* We began monetizing the *2025* credits in *December 2025,* and we are planning to continue to monetize *2026* and later credits on a regular basis. The recent federal tax and budget legislation referred to as the "One Big Beautiful Bill" that was enacted in *July 2025* contains provisions that are expected to increase our future income from Section *45Z* tax credits for RNG production, including an increase in the credit amount earned for each MMBtu of RNG we produce and an extension of the term of the credits to a total of *five* years.

<u>India Biodiesel</u>

*Continue Sales to OMCs*. We plan to continue to operate the Kakinada Plant to produce biodiesel and glycerin and to sell the biodiesel to government-owned Oil Marketing Companies ("OMCs") to help them achieve government mandates to increase the percentage of biodiesel used in India as a percentage of total diesel uses.

*Expand Operations and Plan for IPO*. We have hired a new executive team in India to help develop plans for additional growth of our India business and to execute on a potential initial public offering ("IPO") of stock in our India subsidiary.

*Maintain Self-Sustaining Cash Flow*. Our India business has been self-sustaining in recent years from a cash and liquidity perspective, and we expect this to continue.

***Financing***

While we are implementing our plans to improve liquidity, we have been raising cash for operations by selling equity through our at-the-market stock registration, and we expect to continue to do so. We also plan to seek additional funding for existing and new business opportunities through a combination of working with our senior lender, restructuring or refinancing existing loan agreements, entering into additional debt agreements for specific projects, obtaining project specific equity and debt for development projects, and obtaining additional debt from the current EB-*5* Phase II offering.

***Summary***

Notwithstanding our plans to improve liquidity and the favorable recent events described above, based on the extent of our debt and reliance on our senior secured lender, along with expected near-term shortfalls in cash flow from operations, substantial doubt exists about our ability to continue as a going concern over the next *twelve* months.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *20*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

**Item 2. Management**'**s Discussion and Analysis of Financial Condition and Results of Operations**

*Our Management*'*s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is provided in addition to the accompanying consolidated condensed financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows. MD&A is organized as follows:*

*●* *Overview. Discussion of our business and overall analysis of financial and other highlights affecting us to provide context for the remainder of MD&A.*

*●* *Results of Operations. An analysis of our financial results comparing the three months ended March 31, 2026 and 2025.*

*●* *Liquidity and Capital Resources. An analysis of changes in our balance sheets and cash flows and discussion of our financial condition.*

*●* *Critical Accounting Policies and Estimates. Accounting policies and estimates that we believe are important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.*

*The following discussion should be read in conjunction with our consolidated condensed financial statements and accompanying notes included in Item 1 of Part I of this report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Report and in other reports we file with the SEC. All references to years relate to the calendar year ended December 31 of the particular year.*

**Overview**

Founded in 2006 and headquartered in Cupertino, California, we are a renewable natural gas and biofuels company focused on the operation, acquisition, development, and commercialization of innovative technologies that lower fuel costs and reduce emissions. We operate in three reportable segments consisting of "California Ethanol," "California Dairy Renewable Natural Gas," and "India Biodiesel." We have other operating segments determined *not* to be separately reportable that are collectively represented by the "All Other" category. Our mission is to produce innovative renewable fuel solutions that benefit communities and improve the environment. We are executing our mission by building a circular bioeconomy using agricultural products and waste to produce low carbon renewable fuels that create jobs, reduce greenhouse gas ("GHG") emissions, and improve air quality. For revenue and other information regarding our operating segments, see *Note 13 Segment Information*, of the Notes to Consolidated Financial Statements of this Form 10-Q.

Our California Ethanol segment consists of a 65 million gallon per year capacity ethanol production facility located in Keyes, California (the "Keyes Plant") that we own and operate. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces alcohol for other uses, Wet Distillers Grains ("WDG"), Distillers Corn Oil ("DCO"), and Condensed Distillers Solubles ("CDS"). WDG, DCO, and CDS are sold as animal feed to more than 80 local dairies and feedlots. We also capture the Carbon Dioxide ("CO2") generated by our fermenters and sell it to an industrial gas company that liquifies the CO₂ to sell to food, beverage, and industrial customers. We are implementing several energy efficiency initiatives focused on lowering the carbon intensity ("CI") of our ethanol, primarily by decreasing the use of fossil natural gas. Recently completed energy efficiency projects include high efficiency heat exchangers and a solar micro grid. A significant energy efficiency project in progress is the Mechanical Vapor Recompression ("MVR") system that will use low carbon electricity instead of natural gas. These changes will reduce our energy costs, lower the CI of the ethanol we produce, and generate increased cash flows from LCFS and tax credits. We have already begun procuring MVR equipment and expect the system to be operational in 2026.

Our California Dairy Renewable Natural Gas segment operates anaerobic digesters at local dairies near the Keyes Plant (many of whom also purchase WDG produced by the Keyes Plant as animal feed) to produce biogas from dairy waste, transports the biogas by pipeline to the Keyes Plant site, and converts the biogas to Renewable Natural Gas ("RNG") that is delivered to customers through the utility natural gas pipeline. We currently operate twelve digesters that produce biogas from manure waste received from fifteen dairies, and we are actively growing with additional digesters under construction. We have constructed 36 miles of biogas collection pipeline and have received environmental approval to construct an additional 24 miles of pipeline. We currently have agreements to build digesters and receive waste from over 50 dairies and are seeking to sign agreements with additional dairies.

Our India Biodiesel segment includes a biodiesel production plant in Kakinada, India ("Kakinada Plant") with a production capacity of about 80 million gallons per year. The plant produces high quality distilled biodiesel and refined glycerin for customers in India. We believe the Kakinada Plant is one of the highest capacity biodiesel production facilities in India. The Kakinada Plant is capable of processing a variety of vegetable and animal oil waste feedstocks into biodiesel that meets applicable product standards. Our Kakinada Plant also distills the crude glycerin coproduct from the biodiesel refining process into refined glycerin, which is sold to the pharmaceutical, personal care, paint, adhesive, and other industries.

Our "All Other" segment consists of our projects that are under development, including our planned Carbon Capture and Underground Sequestration ("CCUS") operations and the planned sustainable aviation fuel ("SAF") and renewable diesel ("RD") plant in Riverbank, California. The All Other segment also includes our research and development facility in Minneapolis, Minnesota, operation of the Riverbank Industrial Complex, and our corporate offices in Cupertino, California.

We are developing an SAF/RD production plant that is currently designed to produce 90 million gallons per year of combined SAF/RD or 78 million gallons per year of SAF from feedstocks consisting of renewable waste vegetable and animal oils. Our project is located at the Riverbank Industrial Complex in Riverbank, California. We signed a lease with an option to purchase the Riverbank Industrial Complex in 2021 and took possession of the site in 2022. In 2023, we received a Use Permit and the California Environmental Quality Act ("CEQA") approval for the SAF/RD plant, and in 2024 we received Authority to Construct air permits for the plant. We are continuing with development activities, including engineering and financing. The Riverbank site has access to low carbon hydroelectric power, and our plant is designed to use renewable hydrogen that will be produced from byproducts of the SAF/RD production process.

Our planned CCUS projects will compress and inject CO₂ into deep wells that are monitored to ensure the long-term sequestration of carbon underground. California's Central Valley has been identified as one of the world's most favorable regions for large-scale CO₂ injection projects due to the subsurface geologic formations that absorb and contain CO₂ gas. The two initial Aemetis CCUS injection projects are being designed to capture and sequester more than two million metric tons per year of CO₂ at the Aemetis biofuels plant sites in Keyes and Riverbank, California. Once operational, these projects will generate revenue by selling California LCFS credits and federal Internal Revenue Code Section 45Q tax credits.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

Our Minneapolis, Minnesota research and development laboratory evaluates and develops technologies that would use low carbon intensity and waste feedstocks to produce low or below zero carbon intensity biofuels and biochemicals. We are focused on processes that extract sugar from cellulosic feedstocks and produce low carbon ethanol, renewable hydrogen, SAF, and RD.

**Results of Operations**

**Three Months Ended March 31, 2026, Compared to Three Months Ended March 31, 2025**

***Revenues***

Our revenues are derived primarily from sales of ethanol and WDG at our California Ethanol segment, renewable natural gas ("RNG") environmental attributes at our California Dairy Renewable Natural Gas segment, and biodiesel at our India Biodiesel segment. We also generate IRA Section 45Z Production Tax Credits at the California Ethanol and RNG segments, which we recognize as revenue.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2026** | **2025** | **Inc/(dec)** | **% change** |
| California Ethanol | $38825 | $37748 | $1077 | 2.9% |
| California Dairy Renewable Natural Gas | 5255 | 2443 | 2812 | 115.1% |
| India Biodiesel | 10539 | 2695 | 7844 | 291.1% |
| Total | $54619 | $42886 | $11733 | 27.4% |

---

*California Ethanol.* For the three months ended March 31, 2026, this segment generated 70% of its revenue from sales of ethanol, and the rest from sales of WDG, Corn Oil, CDS, and CO₂. It also generated and recognized $2.6 million in Section 45Z PTC income during the three months ended March 31, 2026; the revenue recognized during same period in 2025 does not include PTC income, as we recognized Section 45Z PTC income for calendar year 2025 in the fourth quarter of 2025, after establishing qualification for the PTCs under the applicable statute and guidance. For the three months ended March 31, 2026, the Keyes Plant sold 13.7 million gallons of ethanol at an average price of $1.97 per gallon and 91.0 thousand tons of WDG at an average price of $84.46 per ton, compared to sales during the three months ended March 31, 2025, when the Keyes Plant sold 14.1 million gallons of ethanol at an average price of $1.98 per gallon and 93.0 thousand tons of WDG at an average price of $86.00 per ton.

*California Dairy Renewable Natural Gas.* During the three months ended March 31, 2026, we sold 109.5 thousand MMBtu ("million British thermal units") of RNG at an average price of 1.98 per MMBtu, compared to the three months ended March 31, 2025, when we sold 70.9 thousand MMBtu of RNG at an average price of $3.65 per MMBtu. During the three months ended March 31, 2026, we sold 801.3 thousand D3 RINs at an average price of $2.41 per D3 RIN, compared to the three months ended March 31, 2025, when we sold 388 thousand D3 RINs at an average price of $2.64 per RIN. During the period ended March 31, 2026, we sold 30.3 thousand LCFS credits at an average price of $55.00 each, compared to 16.0 thousand LCFS credits at an average price of $72.50 each during the period ended March 31, 2025. The RNG segment also generated $1.4 million of Section 45Z PTC income during the three months ended March 31, 2026; the revenue recognized during same period in 2025 does not include PTC income, as we recognized Section 45Z PTC income for calendar year 2025 in the fourth quarter of 2025, after establishing qualification for the PTCs under the applicable statute and guidance.

*India Biodiesel.* In 2025 and 2026, all our India sales of biodiesel were to government owned Oil Marketing Companies ("OMCs") pursuant to the OMC tender and allocation process. For the three months ended March 31, 2026, we generated 90% of our India segment revenues from the sale of biodiesel and 10% from other sales. The increase in revenues was primarily due to delivery on the OMC contracts during the quarter. We sold 9.2 thousand metric tons of biodiesel during the three months ended March 31, 2026, compared to no biodiesel sales during the three months ended March 31, 2025.

***Cost of Goods Sold***

Cost of goods sold consists primarily of feedstock, energy, chemicals, direct costs (principally labor and labor related costs), and overhead. Depending on the costs of these inputs in comparison to the sales price of our end products, our gross margins at any given time can vary from positive to negative. Overhead includes direct and indirect costs associated with plant operations, including the cost of repairs and maintenance, consumables, on-site security, insurance, and depreciation.

We purchase feedstock for the California Ethanol segment from J.D. Heiskell based on daily market prices for corn plus costs of rail transportation, local basis, and a handling fee paid to J.D. Heiskell. The credit term for the corn purchased from J.D. Heiskell is one day, netted from our product sales. Cost of goods sold also includes the cost of electricity and natural gas, chemicals, maintenance, direct labor, depreciation, and freight.

We obtain the feedstock for producing RNG from dairy operators who lease us their land for construction of our digesters and supply our digesters with manure in liquid form. Our cost of feedstock is established by manure supply agreements based on the value of the environmental attributes and the number of cows at each dairy.

We utilize several different feedstocks for the Kakinada Plant, including stearin, a non-edible feedstock, from neighboring natural oil processing plants. Raw material is received by truck and loaded at our vendor's nearby facilities. Credit terms vary by vendor. However, we generally receive 15 days of credit for the purchases. We purchase crude glycerin in the international market on letters of credit or advance payment terms as market prices become viable.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2026** | **2025** | **Inc/(dec)** | **% change** |
| California Ethanol | $38253 | $42686 | $(4433) | (10.4)% |
| California Dairy Renewable Natural Gas | 3181 | 2138 | 1043 | 48.8% |
| India Biodiesel | 10429 | 3142 | 7287 | 231.9% |
| Total | $51863 | $47966 | $3897 | 8.1% |

---

*California Ethanol.* We ground 4.7 million bushels of corn at an average cost of $5.93 per bushel during the three months ended March 31, 2026, compared to 4.8 million bushels of corn at an average cost of $6.63 per bushel during the three months ended March 31, 2025. The decrease in cost of goods sold for the three months ended March 31, 2026, is mainly due to the planned reduction in the quantity of corn ground during the first two months of the quarter, along with an 11% decrease in the average corn price per bushel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

*California Dairy Renewable Natural Gas.* Cost of goods sold increased as a result of the increased manure costs, digester maintenance expenses, and depreciation from additional digesters placed into service.

*India Biodiesel.* The increase in cost of goods sold during the three months ended March 31, 2026, compared to March 31, 2025, was attributable to an increase in biodiesel sales.

***Gross Profit (Loss)***

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2026** | **2025** | **Inc/(dec)** | **% change** |
| California Ethanol | $572 | $(4938) | $5510 | (111.6)% |
| California Dairy Renewable Natural Gas | 2074 | 305 | 1769 | 580.0% |
| India Biodiesel | 110 | (447) | 557 | (124.6)% |
| Total | $2756 | $(5080) | $7836 | (154.3)% |

---

*California Ethanol.* The gross profit during the three months ended March 31, 2026, compared to a gross loss during the same period in 2025, was attributable primarily to reduced volumes and reduced corn costs, as well as the $2.6 million of Section 45Z PTC income recognized during the three months ended March 31, 2026, but not during the three months ended March 31, 2025.

*California Dairy Renewable Natural Gas.* The increase in gross profit for the three months ended March 31, 2026, compared to the same period in 2025, is due to the increase in RNG production and associated environmental attributes, as well as the $1.4 million of Section 45Z PTC income recognized during the three months ended March 31, 2026, but not during the three months ended March 31, 2025.

*India Biodiesel.* The gross profit for the three months ended March 31, 2026, compared to the loss during same period in 2025, reflects the resumption of sales of biodiesel and refined glycerin.

***Operating Expenses and Other Expenses***

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2026** | **2025** | **Inc/(dec)** | **% change** |
| Selling, general and administrative | 9091 | 10475 | (1384) | (13.2)% |
| Other expense (income): |  |  |  |  |
| Interest expense |  |  |  |  |
| Interest rate expense | $12403 | $11018 | $1385 | 12.6% |
| Debt related fees and amortization expense | 1971 | 2675 | (704) | (26.3)% |
| Accretion and other expenses of Series A preferred units | 1613 | 2279 | (666) | (29.2)% |
| Other income | (478) | (215) | (263) | 122.3% |

---

SG&A expenses consist primarily of salaries and related expenses for employees, marketing expenses related to sales of ethanol and WDG in California Ethanol and biodiesel and other products in India Biodiesel, as well as professional fees, insurance, other corporate expenses, and related facility expenses. SG&A expenses as a percentage of revenue were 17% in the three months ended March 31, 2026, compared to 24% in the three months ended March 31, 2025. SG&A expense decreased compared to the same period in the prior year, while revenue increased during the three months ended March 31, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other expenses consist primarily of interest and amortization expense on debt and accretion of the liability to repurchase Biogas Series A Preferred Units. The cost of debt includes issuance of warrants as renewal fees. The fair value of stock and warrants are amortized as expenses, except when the extinguishment accounting method is applied, in which case refinanced debt costs are recorded as extinguishment expense. Interest expense increased during the three months ended March 31, 2026, due to higher variable interest rates and higher debt balances.

**Liquidity and Capital Resources**

***Cash and Cash Equivalents***

Cash and cash equivalents were $4.8 million at March 31, 2026, with $4.3 million held in our North American entities and $0.5 million in our India entity. We expect that our future available cash resources will be generated from operations, sales of equity, sales of tax credits, and new debt. Incurrence of new debt and the associated use of proceeds from future debt financings are subject to approval by our senior lender.

***Liquidity***

Cash and cash equivalents, current assets, current liabilities, and debt at the end of each period were as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **March 31, 2026** | **December 31, 2025** |
| Cash and cash equivalents | $4797 | $4894 |
| Current assets (including cash, cash equivalents, and deposits) | 34687 | 26872 |
| Current and long-term liabilities (excluding all debt) | 186787 | 184908 |
| Current & long-term debt | 404680 | 381764 |

---

Our principal sources of liquidity have been cash provided by operations, the sale of equity, and borrowings under various debt arrangements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

We operate in a volatile market in which we have limited control over major components of input costs and product revenues. We are making investments in future facilities and facility upgrades that improve overall margins while lessening the impact of volatile markets. As such, we expect cash provided by operating activities to fluctuate in future periods primarily because of changes in the prices for corn, ethanol, WDG, DCO, CDS, biodiesel, waste fats and oils, glycerin, non-refined palm oil, natural gas, LCFS credits, and D3 RINs. To the extent that we experience periods in which the spread between ethanol prices and corn and energy costs narrow or the value of environmental attributes or tax credits is reduced, we require additional working capital to fund operations.

The India Biodiesel segment utilized its receivables financing facility during the quarter to support short-term liquidity needs. Although the facility was fully repaid by quarter-end, it remains available for future use. We believe this arrangement provides flexibility in managing cash flows while maintaining prudent risk oversight.

We are implementing several strategies to improve our cash flow from operations, as described in more detail in *Note 16 Liquidity* of the Notes to our Consolidated Financial Statements in this Form 10-Q.

***Senior Secured Debt***

As of March 31, 2026, the outstanding balance of principal, interest and fees, net of discounts, on all Third Eye Capital Notes totals $262.2 million, which is all due on demand by the lender. Third Eye Capital has provided a series of accommodating amendments to our debt facilities as described in further detail in *Note 5 Debt* of the Notes to Consolidated Financial Statements in this Form 10-Q. However, future amendments or accommodations will continue to be at the discretion of the lender. In the event our senior lender demands the debt in full, we would likely not have sufficient cash to pay the debt when due unless we are able to obtain alternative financing.

***Change in Debt, Working Capital and Cash Flows***

The following table describes the changes in current and long-term debt (in thousands) during the three months ended March 31, 2026:

---

| | | |
|:---|:---|:---|
| Increases to debt: |  |  |
| Accrued interest | $12846 |  |
| Maturity date extension fee and other fees added to senior debt | 1700 |  |
| Change in debt issuance costs, net of amortization | 933 |  |
| Secured loans and Working capital loan draw | 10896 |  |
| TEC short term promissory note | 1800 |  |
| Construction loan short term borrowings | 3945 |  |
| Total increases to debt |  | $32120 |
| Decreases to debt: |  |  |
| Principal and interest payments and reductions to EB-5 promissory note | (6) |  |
| Term Loan Payments | (8) |  |
| Construction Term Loan Payments | (1418) |  |
| Secured loans and Working capital loans payments | (7756) |  |
| Payments on Term loans for capital expenditures | (14) |  |
| Reclass to accounts payable for payment | (2) |  |
| Total decreases to debt |  | $(9204) |
| **Change in total debt** |  | $22916 |

---

Cash used in operating activities was $10.6 million, derived from a net loss of $21.7 million, non-cash changes of $8.2 million, and changes in operating assets and liabilities of $3.0 million. The non-cash changes primarily consisted of: (i) $1.7 million in stock-based compensation expense, (ii) $2.5 million in depreciation expenses, (iii) $2.0 million in amortization of debt issuance costs and other intangible assets, (iv) $1.6 million in preferred unit accretion and other expenses of Series A Preferred Units. Cash increases related to changes in operating assets and liabilities consisted primarily of (i) a decrease in inventory of $0.8 million primarily due to the India biodiesel segment selling biodiesel inventory, and (ii) a $1.2 million increase in accounts payable. This was offset by (i) a $6.6 million increase in accounts receivable, and (ii) a $3.7 million increase in the balance of other current assets primarily from earning Section 45Z PTCs.

Cash used in investing activities was $5.1 million, of which $6.5 million was primarily used for capital projects associated with production of RNG and energy efficiency projects in California offset by $1.4 million grants received.

Cash provided by financing activities was $14.7 million, consisting primarily of (i) $16.0 million proceeds from borrowings, and (ii) $6.6 million from sales of common stock, offset by $7.9 million in repayments of borrowings.

Our ongoing at-the-market stock sales registration allows us to sell shares of common stock into the publicly traded market. During the three months ended March 31, 2026, we sold 2.6 million shares of common stock for proceeds of $6.6 million net of commissions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

**Critical Accounting Policies and Estimates**

Our discussion and analysis of financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported net sales and expenses for each period. We believe that of our most significant accounting policies and estimates, defined as those policies and estimates that we believe are the most important to the portrayal of our financial condition and results of operations and that require management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain are: liquidity; debt covenant forecast; and recoverability of long-lived assets. These significant accounting principles are more fully described in "Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies" in our Annual Report on Form 10-K for the year ended December 31, 2025.

**Recently Issued Accounting Pronouncements**

None reported beyond those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.

**Off Balance Sheet Arrangements**

None.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk.**

Not applicable.

**Item 4. Controls and Procedures.**

***Evaluation of Disclosure Controls and Procedures.***

As of the end of the period covered by this Quarterly Report on Form 10-Q, the Company's management, with the participation of the Company's Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based on that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective as of the end of the period covered by this report.

***Changes in Internal Control over Financial Reporting.***

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2026, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Tabular data in thousands, except par value and per share data)

[**Table of Contents**](#toc)

**PART II -- OTHER INFORMATION**

**Item 1. Legal Proceedings.**

None.

**Item 1A. Risk Factors.**

Not applicable.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

In January 2026, we issued 112,733 shares of Aemetis, Inc. common stock to two lenders in connection with the lenders' exercise of warrants issued during the prior quarter. The issuance of the shares was exempt from registration under Section 4(2) of the Securities Act of 1933, as amended, as issuances of securities not involving any public offering.

In February 2026, we issued 35,212 shares of Aemetis, Inc. common stock to a vendor in connection with a services agreement at an effective value of $1.42 per share, which was the closing price on the Nasdaq market on the date prior to such issuance. The issuance of the shares was exempt from registration under Section 4(2) of the Securities Act of 1933, as amended, as an issuance of securities not involving any public offering.

In March 2026, we issued a stock option pursuant to the 2019 Stock Plan to a consultant that is exercisable for 6,000 shares of Aemetis, Inc. common stock at an exercise price of $2.64 per share, which was the market price of our common stock on the day of issuance. The stock option has a term of 10 years, and one-twelfth of the shares vest every three months over a three-year period from the grant date. The issuance of this stock option and the future issuance of shares upon exercise of the option are exempt from registration under Section 4(2) of the Securities Act of 1933, as amended, as an issuance of securities not involving any public offering.

**Item 3. Defaults Upon Senior Securities.**

No unresolved defaults on senior securities occurred during the three months ended March 31, 2026.

**Item 4. Mine Safety Disclosures.**

None.

**Item *5.* Other Information.**

*Current Report*

On *May 5, 2026,* Aemetis Biogas LLC ("ABGL") entered into an agreement titled Twelfth Waiver and Amendment to Series A Preferred Unit Purchase Agreement ("PUPA Twelfth Amendment") with an effective date of *April 30, 2026,* that requires, among other provisions, ABGL to either (i) redeem all outstanding Series A Preferred Units by *August 31, 2026,* for an aggregate redemption price of $116.7 million or (ii) enter into a credit agreement in the form attached to the PUPA Twelfth Amendment. The PUPA Twelfth Amendment is attached as Exhibit *10.1* to this Form *10*-Q and is described in the notes to the Financial Statements in Part I Item *1* of this Form *10*-Q under *Note *15* Subsequent Events*. This description is a summary only and is qualified by the text of the attached Exhibit *10.1.*

**Item 6. Exhibits.**

---

| | |
|:---|:---|
| 10.1 | [Twelfth Waiver and Amendment to Series A Preferred Unit Purchase Agreement, effective April 30, 2026, between Aemetis Biogas LLC, Protair-X Technologies Inc., and Third Eye Capital Corporation](ex_956856.htm) |
| 31.1 | [Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_904795.htm) |
| 31.2 | [Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_904796.htm) |
| 32.1 | [Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_904797.htm) |
| 32.2 | [Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_904798.htm) |
| 101.INS \* | Inline XBRL Instance Document |
| 101.SCH \* | Inline XBRL Taxonomy Extension Schema |
| 101.CAL \* | Inline XBRL Taxonomy Extension Calculation Linkbase |
| 101.DEF \* | Inline XBRL Taxonomy Extension Definition Linkbase |
| 101.LAB \* | Inline XBRL Taxonomy Extension Label Linkbase |
| 101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26

------

[**Table of Contents**](#toc)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Aemetis, Inc.** | **Aemetis, Inc.** |
| Date: May 7, 2026 | By: | /s/ Eric A. McAfee |
|  |  | Eric A. McAfee<br> Chair of the Board and Chief Executive Officer<br> (Principal Executive Officer) |

---

---

| | | |
|:---|:---|:---|
| Date: May 7, 2026 | By: | /s/ Todd Waltz |
|  |  | Todd Waltz<br> Executive Vice President and Chief Financial Officer<br> (Principal Financial Officer) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27

## Exhibit 10.1

**Exhibit 10.1**

**TWELFTH WAIVER AND AMENDMENT TO**

**SERIES A PREFERRED UNIT PURCHASE AGREEMENT**

This Twelfth Waiver and Amendment to Series A Preferred Unit Purchase Agreement (this "**Amendment**"), effective as of April 30, 2026 ("**Effective Date**") , is made by and among (i) **AEMETIS BIOGAS LLC**, a Delaware limited liability company ("**ABGL**" or "**COMPANY**"), (ii) **PROTAIR-X TECHNOLOGIES INC.**, a Canadian corporation (the "**Purchaser**"), and (iii) **THIRD EYE CAPITAL CORPORATION**, an Ontario corporation, as agent for the Purchaser ("**Agent**").

**<u>RECITALS</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. ABGL, the Agent, and the predecessor of the Purchaser entered into the Series A Preferred Unit Purchase Agreement and a Security Agreement, each dated as of December 20, 2018 (as amended, the "**Agreement** "). Capitalized terms used but not defined in this Amendment shall have the meaning given to them in the Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. Prior to the effectiveness of this Amendment, Section 6.9(b) required ABGL to redeem the outstanding Series A Preferred Units by April 30, 2026, or, if not redeemed, to enter into a Credit Agreement with Purchaser and Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. ABGL has not redeemed all of the outstanding Series A Preferred Units, and the Parties hereto desire to extend the deadline for such redemption, pursuant to ABGL's ongoing negotiations with certain strategic investors in order to conclude an optimal transaction by the dates indicated herein and in advance of the Final Redemption Date, and the parties have agreed to amend the Agreement and to provide certain consents and waivers on the terms and conditions contained herein to contemplate the foregoing.

**<u>AGREEMENT</u>**

SECTION 1. **<u>Waiver and Amendments</u>**. The Agent and Purchaser hereby waive, as of the date hereof, non-compliance with Section 6.9(b) the Agreement that occurred prior to the Effective Date and agree that the following sections of the Agreement shall be and hereby are amended as follows:

&nbsp;&nbsp;&nbsp;&nbsp;(A) **<u>Section 6.9(b) (Full Redemption)</u>**. Subsection 6.9(b) of the Agreement is deleted in its entirety and replaced with the following:

<u>"Full Redemption</u>. On or before 2:00pm EST on August 31, 2026 (the "**Final Redemption Date**"), the Company shall redeem all of the outstanding Series A Preferred Units by paying to the Purchaser, in immediately available funds, an aggregate amount equal to $97,229,896.97 (being equal to $135,500,000 less $38,270,103.03 received by the Purchaser) (the "**Final Redemption Price**"). The payment and receipt of the Final Redemption Price shall be in full and complete satisfaction of the requirement of the Company to pay the Obligations under the Agreement, and upon receipt of such payment and the payment of any outstanding fees or other amounts, the Purchaser shall deliver to the Company for cancellation, the certificate or certificates representing the then issued and outstanding Series A Preferred Units held by the Purchaser or on its behalf, and the Agreement and other Transaction Documents shall be deemed terminated (except for any provisions thereof that, by their specific terms, survive termination). Notwithstanding the foregoing, the Parties acknowledge that they shall continue negotiations, in good faith, towards ensuring the redemption transaction noted herein on the Final Redemption Date is done on a tax efficient basis, including giving consideration to a transaction involving the sale of the Purchaser to the Company or its shareholder or other affiliates."

<u>Credit Agreement</u>. In the event that the Final Redemption Price is not paid by the date indicated above, such failure shall constitute a Trigger Event, and in addition to the remedies indicated in Section 7.2 of the Agreement, the Company agrees that effective as of September 1, 2026, it will execute and agree to be bound by, and shall irrevocably be deemed to have entered into, a credit agreement with the Agent and the Purchaser in substantially the form attached as Schedule "A" to the Twelfth Amendment (with any revisions required and agreed to by the parties in order to ensure such transaction is done on a tax efficient basis, the "**Credit Agreement**"), and together with any ancillary agreements, documents, certificates, guarantees or deliverables contemplated by such Credit Agreement (collectively, the "**Credit Documents**"), and such Credit Agreement shall be a modification and replacement of this Agreement, and the liabilities, obligations, covenants and requirements of this Agreement shall be replaced by the liabilities, obligations, covenants and requirements of the Credit Agreement and all such security, liens and registrations provided pursuant to this Agreement (or ancillary agreements) shall continue and remain in place unaffected. Further, upon execution of the Credit Agreement and all Credit Documents (including without limitation any guarantees which the Credit Agreement contemplates to be signed by affiliates of ABGL, including those signatories to the Twelfth Amendment), the Purchaser shall deliver to the Company for cancellation, the certificate or certificates representing the then issued and outstanding Series A Preferred Units held by the Purchaser or on its behalf, and the Agreement and other Transaction Documents shall be deemed terminated (except for any provisions thereof that, by their nature, survive termination)."

&nbsp;&nbsp;&nbsp;&nbsp;(B) **<u>Section 1.1 Defined Terms</u>**. The following defined term is added into Section 1.1 of the Agreement in its applicable alphabetical order:

**"Twelfth Amendment**" means that Twelfth Waiver and Amendment to Series A Preferred Unit Purchase Agreement dated as of April 30, 2026, by and between the Company, the Purchaser and the Agent."

SECTION 2. **<u>Conditions to Effectiveness</u>**. This Amendment shall be subject to satisfaction of the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;(a) ABGL shall have performed and complied with all of the covenants and conditions required by this Amendment and the Transaction Documents to be performed and complied with upon the effective date of this Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;(b) ABGL shall pay, on the Final Redemption Date, a closing fee of $19,500,000, payable to or at the direction of, the Purchaser (and for, purposes of clarity, this closing fee is in addition to the Final Redemption Price and may be paid by entry of the Credit Agreement, and the closing fee is included in the $116,729,896.97 principal referred to in the form of Credit Agreement).

&nbsp;&nbsp;&nbsp;&nbsp;(c) Agent shall have received all other approvals, opinions, documents, agreements, instruments, certificates, schedules and materials as the Agent may reasonably request, including tax advice to ensure that the transactions contemplated herein are done on a tax efficient manner.

SECTION 3. **<u>Acknowledgement</u>**. ABGL acknowledges and agrees that the failure to perform, or to cause the performance of, the covenants and agreements in this Amendment will constitute a Trigger Event under the Agreement.

SECTION 4. **<u>Agreement in Full Force and Effect as Amended</u>**. Except as specifically amended or waived hereby, the Agreement and other Transaction Documents shall remain in full force and effect and are hereby ratified and confirmed as so amended. Except as expressly set forth herein, this Amendment shall not be deemed to be a waiver, amendment or modification of, or consent to or departure from, any provisions of the Agreement or any other Transaction Document or any right, power or remedy of the Agent or Purchaser thereunder, nor constitute a waiver of any provision of the Agreement or any other Transaction Document, or any other document, instrument or agreement executed or delivered in connection therewith or of any Trigger Event under any of the foregoing, in each case whether arising before or after the execution date of this Amendment or as a result of performance hereunder or thereunder. This Amendment shall not preclude the future exercise of any right, remedy, power, or privilege available to the Agent or Purchaser whether under the Agreement, the other Transaction Documents, at law or otherwise. All references to the Agreement shall be deemed to mean the Agreement as modified hereby. This Amendment shall not constitute a novation or satisfaction and accord of the Agreement or any other Transaction Document but shall constitute an amendment thereof. The parties hereto agree to be bound by the terms and conditions of the Agreement and Transaction Documents as amended by this Amendment, as though such terms and conditions were set forth herein. Each reference in the Agreement to "this Agreement," "hereunder," "hereof," "herein" or words of similar import shall mean and be a reference to the Agreement as amended by this Amendment, and each reference herein or in any other Transaction Documents to "the Agreement" shall mean and be a reference to the Agreement as amended and modified by this Amendment.

------

SECTION 5. **<u>Representations by ABGL</u>**. ABGL hereby represents and warrants to the Agent and Purchaser as of the execution date of this Amendment as follows: (a) it is duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation; (b) the execution, delivery and performance by it of this Amendment are within its powers, have been duly authorized, and do not contravene (i) its articles of incorporation, bylaws or other organizational documents, or (ii) any applicable law; (c) no consent, license, permit, approval or authorization of, or registration, filing or declaration with any Governmental Authority or other Person is required in connection with the execution, delivery, performance, validity or enforceability of this Amendment; (d) this Amendment has been duly executed and delivered by it; (e) this Amendment constitutes its legal, valid and binding obligation enforceable against it in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors' rights generally or by general principles of equity; (f) it is not in default under the Agreement or any other Transaction Documents and no Trigger Event exists, has occurred and is continuing or would result by the execution, delivery or performance of this Amendment; and (g) the representations and warranties contained in the Agreement and the other Transaction Documents are true and correct in all material respects as of the execution date of this Amendment as if then made, except for such representations and warranties limited by their terms to a specific date.

SECTION 6. **<u>Miscellaneous</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;(A) This Amendment may be executed in any number of counterparts (including by facsimile or email), and by the different parties hereto on the same or separate counterparts, each of which shall be deemed to be an original instrument but all of which together shall constitute one and the same agreement. Each party agrees that it will be bound by its own facsimile or scanned signature and that it accepts the facsimile or scanned signature of each other party. The descriptive headings of the various sections of this Amendment are inserted for convenience of reference only and shall not be deemed to affect the meaning or construction of any of the provisions hereof or thereof. The use of the word "including" in this Amendment shall be by way of example rather than by limitation. The use of the words "and" or "or" shall not be inclusive or exclusive.

&nbsp;&nbsp;&nbsp;&nbsp;(B) This Amendment may not be changed, amended, restated, waived, supplemented, discharged, canceled, terminated or otherwise modified without the written consent of the parties hereto. This Amendment shall be considered part of the Agreement and shall be a Transaction Document for all purposes.

&nbsp;&nbsp;&nbsp;&nbsp;(C) This Amendment, the Agreement and the Transaction Documents constitute the final, entire agreement and understanding between the parties with respect to the subject matter hereof and thereof and may not be contradicted by evidence of prior, contemporaneous or subsequent oral agreements between the parties, and shall be binding upon and inure to the benefit of the successors and assigns of the parties hereto and thereto. There are no unwritten oral agreements between the parties with respect to the subject matter hereof and thereof.

&nbsp;&nbsp;&nbsp;&nbsp;(D) THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS AMENDMENT SHALL BE GOVERNED BY AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH THE CHOICE OF LAW PROVISIONS SET FORTH IN THE AGREEMENT AND SHALL BE SUBJECT TO THE WAIVER OF JURY TRIAL AND NOTICE PROVISIONS OF THE AGREEMENT.

&nbsp;&nbsp;&nbsp;&nbsp;(E) ABGL may not assign, delegate or transfer this Amendment or any of its rights or obligations hereunder. No rights are intended to be created under this Amendment for the benefit of any third-party donee, creditor or incidental beneficiary. Nothing contained in this Amendment shall be construed as a delegation to Agent or the Purchaser of ABGL's duty of performance, including any duties under any account or contract in which the Agent or Purchaser have a security interest or lien. This Amendment shall be binding upon the parties hereto and their respective successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;(F) ABGL ACKNOWLEDGES THAT ITS PAYMENT OBLIGATIONS ARE ABSOLUTE AND UNCONDITIONAL WITHOUT ANY RIGHT OF RECISSION, SETOFF, COUNTERCLAIM, DEFENSE, OFFSET, CROSS-COMPLAINT, CLAIM OR DEMAND OF ANY KIND OR NATURE WHATSOEVER THAT CAN BE ASSERTED TO REDUCE OR ELIMINATE ALL OR ANY PART OF ITS LIABILITY TO REPAY THE "OBLIGATIONS" OR TO SEEK AFFIRMATIVE RELIEF OR DAMAGES OF ANY KIND OR NATURE FROM AGENT OR PURCHASER. ABGL HEREBY VOLUNTARILY AND KNOWINGLY RELEASES AND FOREVER DISCHARGES THE AGENT AND PURCHASER AND THEIR RESPECTIVE PREDECESSORS, ADMINISTRATIVE AGENTS, EMPLOYEES, SUCCESSORS AND ASSIGNS (COLLECTIVELY, THE "RELEASED PARTIES") FROM ALL POSSIBLE CLAIMS, DEMANDS, ACTIONS, CAUSES OF ACTION, DAMAGES, COSTS, EXPENSES, AND LIABILITIES WHATSOEVER, KNOWN OR UNKNOWN, ANTICIPATED OR UNANTICIPATED, SUSPECTED OR UNSUSPECTED, FIXED, CONTINGENT, OR CONDITIONAL, AT LAW OR IN EQUITY, ORIGINATING IN WHOLE OR IN PART ON OR BEFORE THE DATE THIS AMENDMENT IS EXECUTED, WHICH SUCH PERSON MAY NOW OR HEREAFTER HAVE AGAINST THE RELEASED PARTIES, IF ANY, AND IRRESPECTIVE OF WHETHER ANY SUCH CLAIMS ARISE OUT OF CONTRACT, TORT, VIOLATION OF LAW OR REGULATIONS, OR OTHERWISE, INCLUDING ANY CONTRACTING FOR, CHARGING, TAKING, RESERVING, COLLECTING OR RECEIVING INTEREST IN EXCESS OF THE HIGHEST LAWFUL RATE APPLICABLE, THE EXERCISE OF ANY RIGHTS AND REMEDIES UNDER THE AGREEMENT OR OTHER TRANSACTION DOCUMENTS, AND NEGOTIATION FOR AND EXECUTION OF THIS AMENDMENT.

*{Signatures appear on following pages.}*

------

IN WITNESS WHEREOF, the parties hereto have executed this Amendment.

**AEMETIS BIOGAS LLC**

By:<u> </u><u> </u><u> </u><u> </u><u> </u> <u>/s/</u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><br> Name: Eric A. McAfee<br> Title: Chief Executive Officer

**THIRD EYE CAPITAL CORPORATION**

By:<u> </u><u> </u><u> </u><u> </u><u> </u> <u>/s/</u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><br> Name: Arif N. Bhalwani<br> Title: Managing Director

**PROTAIR-X TECHNOLOGIES INC.**

By:<u> </u><u> </u><u> </u><u> </u><u> </u> <u>/s/</u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><br> Name: Michael Niklaus<br> Title: Chief Executive Officer

------

Acknowledged and agreed, specifically with respect to the obligation to provide the Guarantees and security agreements, in a form to be agreed to by the parties thereto, to be provided pursuant to the Credit Agreement, if and when required:

**AEMETIS, INC.**

**GOODLAND ADVANCED FUELS, INC.**

**AEMETIS CARBON CAPTURE, INC.**

**AEMETIS ADVANCED PRODUCTS KEYES, INC., AEMETIS ADVANCED FUELS KEYES, INC., AEMETIS PROPERTY KEYES, INC., AEMETIS RIVERBANK, INC., AEMETIS PROPERTIES RIVERBANK, INC., AEMETIS ADVANCED PRODUCTS RIVERBANK, INC., AEMETIS HEALTH PRODUCTS, INC., AEMETIS INTERNATIONAL, INC., AEMETIS TECHNOLOGIES, INC., AE ADVANCED FUELS, INC., AEMETIS BIOFUELS, INC., AEMETIS AMERICAS, INC., AEMETIS ADVANCED FUELS, INC., AEMETIS FACILITY KEYES, INC., ENERGY ENZYMES, INC., AE BIOFUELS, INC., AEMETIS ADVANCED BIOREFINERY KEYES, INC.**

By:<u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u>/s/</u> <u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><u> </u><br> Name: Eric A. McAfee<br> Title: Chief Executive Officer

------

**Schedule** "**A**"

Form of Credit Agreement

**CREDIT AGREEMENT**

September 1, 2026

FOR VALUE RECEIVED, the undersigned AEMETIS BIOGAS LLC, a Delaware limited liability company (the "**Borrower**"), promises to pay to the order of THIRD EYE CAPITAL CORPORATION, an Ontario Corporation, as administrative agent and collateral agent (together with its successors and assigns, the "**Agent**") for and on behalf of PROTAIR-X TECHNOLOGIES INC. (including its successors and assigns, the "**Lender**"), at its offices or such other place as the Agent may designate in writing the amounts that may be outstanding from time to time hereunder pursuant to the term loan facility (the "**Facility**"), as indicated pursuant to the records of the Agent with respect to such amounts, together with interest on the amount remaining unpaid from time to time from the date of this credit agreement ("**Credit Agreement**") until due and payable, at the Interest Rate (defined below), as more particularly set out in Section 3 hereto. The Lender's obligation hereunder shall be limited to the maximum commitment equal to $116,729,896.97, to be drawn in a single advance on the date hereof. All references to "$" or "dollars" is to the lawful currency of the United States and all capitalized terms shall have the definitions indicated herein or in Section 19(h) below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Use of Proceeds**. The Borrower shall use the proceeds of the advance made under the Facility on the date hereof to repurchase for cancellation 100% of those Series A Preferred Shares issued by the Borrower pursuant to that Series A Preferred Unit Purchase Agreement dated December 20, 2018 between the Borrower, the Lender and Third Eye Capital Corporation, as agent thereunder (as may be amended from time to time, the "**PUPA** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **Repayments.** The full outstanding principal balance of the indebtedness evidenced hereby under the Facility, together with all accrued but then unpaid and compounded interest thereon and any other sums due hereunder, shall be due and payable in full at the earlier to occur of: (i) September 1, 2027 (the "**Maturity Date** "), and (ii) the occurrence of an Event of Default.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **Interest.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The outstanding principal under the Facility shall bear interest at a per annum rate equal to the greater of (i) the Prime Rate plus 10.0% and (ii) 16.0%, compounded daily in arrears (the "**Interest Rate** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. If an Event of Default shall have occurred, all outstanding principal of and, to the fullest extent permitted by law, all past due interest and any other past due amounts owing under the Facility shall bear interest at a rate per annum equal to the Interest Rate plus ten percent (10%) per annum (the "**Default Rate** "). Interest payable at the Default Rate shall be payable from time to time on demand.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Interest shall be payable on the outstanding obligations in arrears for the preceding calendar month on the first Business Day of each calendar month. For greater certainty, interest on the unpaid principal balance shall accrue from the date hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. So long as no Event of Default has occurred and is continuing, on each applicable monthly interest payment date, subject to Section 4 hereto, up to 100% of the amount of interest then owing on the Facility may be capitalized to the principal amount outstanding, at the Borrower's option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **Mandatory Repayments**. Within 5 days of the last day of March, June, September and December of each calendar year, the Borrower shall repay to the Facility all of that amount (if positive) which is equal to one hundred percent (100%) of Free Cash Flow (as defined below) which it or any of its subsidiaries receives during the applicable preceding calendar quarter. Mandatory repayments pursuant to this Section 4 shall be made in immediately available funds.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **Prepayments.** The Borrower may, at any time and from time to time, prepay the indebtedness in whole under the Facility without premium or penalty, but with accrued and compounded interest to the date of such prepayment on the amount prepaid. Any notice of optional prepayment is irrevocable and shall be effective only if received by the Agent by 2:00 p.m. (Toronto, Ontario time) on the date that is five (5) Business Days prior to the proposed prepayment. Any notice of optional prepayment shall specify the amount to be prepaid and the date of prepayment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **Record Keeping.** All borrowings and all payments made on account of the principal hereof shall be endorsed by the Agent in its internal records and shall be made a part hereof, provided however that any failure to endorse such information shall not in any manner affect the obligation of the Borrower to make payments of principal and interest in accordance with the terms hereof. All notations on such Agent's internal records as to borrowings and repayments made shall constitute conclusive evidence of such borrowings or repayments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. **Increased Costs.** If, due to either (i) the introduction of or any change (including, without limitation, any change by way of imposition or increase of reserve requirements but excluding the imposition of, or any change in the rate of, any income tax payable by the Agent or any Lender) in or in the interpretation of any law or regulation or (ii) the compliance by the Agent or any Lender with any guideline or request from any central bank or other governmental authority (whether or not having the force of law), there shall be any increase in the cost to the Agent of funding or maintaining the loans or obligations under this Credit Agreement, then the Borrower shall from time to time, upon demand by the Agent, pay to the Agent and/or the Lenders additional amounts sufficient to indemnify the Agent and the Lenders against such increased cost. A certificate as to the amount of such increased cost, submitted to the Borrower by the Agent, shall be conclusive and binding for all purposes, absent manifest error.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **Illegality.** Notwithstanding any other provision hereof, if, in the reasonable opinion of the Agent, it becomes unlawful for a Lender to make or maintain its loan hereunder, then such Lender will promptly so notify the Borrower and the other Lenders and the Borrower will promptly prepay the balance in full together with accrued interest thereon and all other amounts then due and Lenders will have no further obligation to make or maintain the loan hereunder.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. **Payments and Computations.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The Borrower shall make each payment hereunder not later than 2:00 p.m. (Toronto, Ontario time) on the day when due to the Agent at its address referred to in Section 19(g) or at such other location as may be specified by the Agent to the Borrower, in immediately available funds without setoff, compensation, counterclaim, recoupment or other defense. Any payments received after 2:00 p.m. (Toronto time) will be considered for all purposes as having been made on the next following Business Day.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Agent and Lenders will maintain in accordance with their usual practice one or more accounts evidencing the indebtedness of the Borrower to the Agent hereunder. Such account(s) will be *prima facie* evidence of the obligations recorded therein, provided that any failure by Agent to maintain any account or any error therein shall not affect the obligation of the Borrower to repay its indebtedness to the Agent in accordance with this Credit Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Each determination of a rate of interest or fee by Agent will be conclusive evidence of such rate or fee in the absence of manifest error. Interest and fees will be calculated on the basis of a year of 365 days for the actual number of days (including the first day but excluding the last day) elapsed in the period for which such interest or fees are payable. For the purposes of disclosure pursuant to the *Interest Act* (Canada) and not for any other purpose, where in this Credit Agreement a rate is to be calculated on the basis of a year of 365 days, the yearly rate to which the 365-day rate is equivalent is such rate multiplied by the number of days in the year for which such calculation is made and divided by 365.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Whenever any payment hereunder shall be stated to be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day, and such extension of time shall in such case be included in the computation of payment of interest.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. **Taxes.** The Borrower agrees that all payments to be made by it hereunder and the other Loan Documents shall be made without setoff, compensation or counterclaim and free and clear of, and without deduction for, any taxes, levies, imposts, duties, charges, fees, deductions, withholdings or restrictions or conditions of any nature whatsoever now or hereafter imposed, levied, collected, withheld or assessed by any country or by any political subdivision or taxing authority thereof or therein ()"**Taxes** "). If any Taxes are required to be withheld from any amounts payable to the Agent hereunder, the amounts so payable to the Agent shall be increased to the extent necessary to yield to the Agent (after payment of all Taxes) the amounts payable hereunder in the full amounts so to be paid. Whenever any Tax is paid by the Borrower, as promptly as possible thereafter, the Borrower shall send the Agent an official receipt showing payment thereof, together with such additional documentary evidence as may be required from time to time by the Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. **Maximum Interest Rate.** Notwithstanding any other provisions hereof or any other Loan Document: (i) in no event shall the aggregate "interest" payable to Agent and Lenders hereunder or the other Loan Documents exceed the effective annual rate of interest legally permitted under any Law in any relevant jurisdiction; and (ii) if any provision of this Credit Agreement or any other Loan Document would obligate the Borrower to make any payment of interest or other amount payable to Agent and Lenders in an amount or calculated at a rate which would be prohibited by Law or would result in a receipt by Agent or any Lender of interest at a criminal rate, then notwithstanding such provision, such amount or rate shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest, as the case may be, as would not be so prohibited by Law or so result in a receipt by Agent or any Lender of interest at a criminal rate, such adjustment to be effected, to the extent necessary, as follows: (A) first, by reducing on a *pro rata* basis the amount or rates of interest required to be paid under Section 3 hereof, and (B) thereafter, by reducing any fees, commissions, premiums and other amounts which would constitute interest for purposes of any Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. **Application of Payments.** Prior to the occurrence of an Event of Default, all amounts received by the Agent or the Lenders from the Borrower in respect hereof shall be applied *pro tanto* to the obligations hereunder as follows: first, to pay any fees, indemnities or expense reimbursements then due to the Agent and the Lenders under the Loan Documents, until paid in full, second, to pay interest due, and third, to pay or prepay the principal amount and all outstanding obligations hereunder until paid in full. Upon the occurrence and during the continuance of an Event of Default, all amounts received by the Agent from the Borrower or any other Person shall be applied *pro tanto* to the obligations hereunder in such manner as the Agent shall determine in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. **Representations and Warranties.** The Borrower represents and warrants to the Agent as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. It (i) is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, (ii) has the power and authority, and the legal right, to own and operate its property and to conduct the business in which it is currently engaged, (iii) is duly qualified as a foreign corporation and in good standing under the laws of each jurisdiction where its ownership, lease or operation of property or the conduct of its business requires such qualification and (iv) is in compliance with all requirements of Law in all material respects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. It has the power and authority, and the legal right, to make, deliver and perform the Loan Documents to which it is a party, to consummate the transactions contemplated thereby and, as the case may be, to obtain extensions of credit hereunder. It has taken all necessary organizational action to authorize the execution, delivery and performance of the Loan Documents to which it is a party and to authorize the extensions of credit on the terms and conditions of this Agreement. No consent or authorization of, filing with, notice to or other act by or in respect of, any Governmental Authority or any other Person is required in connection with the extension of credit hereunder or with the execution, delivery, performance, validity or enforceability of this Agreement or any of the Loan Documents. Each Loan Document to which it is a party has been duly executed and delivered on behalf of it. This Agreement constitutes, and each other Loan Document upon execution will constitute, a legal, valid and binding obligation of it, enforceable in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors' rights generally and by general equitable principles (whether enforcement is sought by proceedings in equity or at law).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. The execution, delivery, and performance by it of this Agreement and the other Loan Documents to which it is a party and compliance with the terms and provisions hereof and thereof will not (i) violate or conflict with, or result in a breach of, or require any consent under (A) its constating documents, (B) any Law, or (C) any material agreement or instrument to which it is a party or by which it or any of its properties is bound or subject, or (ii) result in the creation or imposition of any lien upon any of its revenues or assets other than the liens arising under the Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. It is in compliance in all material respects with the Foreign Corrupt Practices Act, as amended, and rules and regulations thereunder ("FCPA"). No part of the proceeds of any advance will be used directly or indirectly for any payments to any governmental official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the FCPA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. There are no actions, suits, litigation or proceedings, at law or in equity, pending by or against it before any court, administrative agency, or arbitrator in which a likely adverse decision could reasonably be expected to have a material adverse effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. It has filed all federal and other material tax returns required to be filed, including all income, franchise, employment, property, and sales tax returns, and has paid all of their respective federal and other material taxes, assessments, governmental charges, and other levies that are due and payable, except to the extent such taxes are contested in good faith by proper proceedings which stay the imposition of any penalty, fine or lien resulting from the non-payment thereof and with respect to which adequate reserves have been set aside for the payment thereof. It has no knowledge of any pending investigation by any taxing authority or of any pending unassessed tax liability (other than taxes which are not yet due and payable).

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. **Conditions to Closing**. The Lender's obligation to provide the Facility is subject to the following conditions being satisfied to the satisfaction of the Agent:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. the Agent shall be satisfied with its tax structuring and planning with respect to the Facility and the repayment and satisfaction of the PUPA;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. delivery of original Loan Documents, each duly executed by the applicable guarantors and affiliates of the Borrower, and applicable financing statements and registrations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. a copy of the annual budget for the current fiscal year and a copy of the annual monthly cash flow budget for each month prior to the Maturity Date ()"**Project Budget** ");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. no Event of Default shall have occurred and be continuing or result from the execution of this Agreement and the other Loan Documents or the advance of funds hereunder; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. the Agent and the Lender shall have received such other documents, instruments and information as reasonably requested.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. **Covenants**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. So long as any of the indebtedness or obligations hereunder shall remain unpaid, the Borrower will not, directly or indirectly, without the prior written consent of the Agent, in its sole and absolute discretion:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. *Liens*. Create, incur, assume or suffer to exist any Lien upon any of its property (whether real, personal, tangible or intangible, whether now owned or hereafter acquired.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. *Indebtedness*. Create, incur, assume or suffer to exist any Indebtedness except Permitted Indebtedness. Without the consent of the Agent, amend, modify or change any term or condition of any documentation entered into in connection with any Indebtedness (i) in any manner (i) if the effect of such amendment, modification or change is to restrict in any manner the ability of any Agent or the Lenders to exchange, extend, renew, replace or refinance, in whole or part, any indebtedness under this Agreement or any other Loan Document, or (ii) in any other manner that could be adverse to the interests, rights or remedies of the Agent or any Lender under the Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. *Capital Stock, Dividends, Etc.* (i) Declare or make any distribution or other dividend payment or distribution of assets, properties, cash, rights, obligations or securities on account of any shares of any class, (ii) issue, purchase, redeem or otherwise acquire for value any shares of any class or any warrants, rights or options to acquire any such shares, now or hereafter outstanding or (iii) make any distributions, remuneration or payment in violation of the terms of any applicable subordination terms applicable to any Permitted Indebtedness. Notwithstanding any other term of this Agreement, Borrower and its Subsidiaries shall not, without the prior written consent of the Agent, make any transfer of funds, transfer of Property, or any distributions, remuneration or payment (including any distributions) to any Person, other than payments on account of the indebtedness in accordance with the terms hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. *Investments.* Make any Investment except Permitted Investments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. *Business, Management, Mergers, etc.* (i) make any change in (A) its board of directors or managers, or (B) its capital structure, (ii) make any material change in the nature of the business presently conducted by it; (iii) make any payments on account of new retainers greater than $50,000 or establish or create any trust accounts, (iv) change its name; (v) change its jurisdiction of incorporation or its type of organization (that is, from a corporation) or otherwise amend, modify or change any of its constating documents, as in effect on the date hereof, except any such amendments, modifications or changes that either individually or in the aggregate could not reasonably be expected to have a material adverse effect; (vi) merge, amalgamate or consolidate with or into, or convey, transfer, lease or otherwise dispose of or alienate (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to, or acquire all or substantially all of the assets of, any Person, or dissolve or liquidate or terminate its legal existence, or (vii) make any change in its accounting policies or reporting practices, except as required or permitted by GAAP, or its fiscal year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. *Clauses Restricting Subsidiary Distributions*. Enter into or suffer to exist or become effective any consensual encumbrance or restriction on the ability of any subsidiary to (a) make dividends or distributions in respect of such subsidiaries Free Cash Flow or capital stock or equity held by, or pay any indebtedness owed to, the Borrower, (b) make loans or advances to, or other investments in the Borrower, or (c) transfer any of its assets to the Borrower, except for such encumbrances or restrictions existing under or by reason of any restrictions existing under the Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. *Change of Control*. Cause, permit or suffer, directly or indirectly, any Change of Control to occur, or incorporate or create any new subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h. *Disposition of Property*. Dispose or alienate of any of its property or equity interests in its subsidiaries, whether now owned or hereafter acquired, except dispositions of inventory made in the ordinary course of its business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. *Affiliate Transactions and Intercompany Loans*. Enter into any transaction with any affiliate or subsidiary or any of its directors or senior or executive officers or senior management, or enter into or assume any employment, consulting or analogous agreement or arrangement with any of its directors or senior or executive officers or senior management or make any payment to any of its directors or senior or executive officers or senior management, except in the ordinary course.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. *Bank Accounts*. Open any new bank account.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. *Negative Pledge Clauses*. Enter into or suffer to exist or become effective any agreement that prohibits or limits its ability to create, incur, assume or suffer to exist any Lien upon any of its property or revenues, whether now owned or hereafter acquired, other than this Agreement and the other Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;xx. *Place of Business*. Change the location of its respective chief executive office, principal place of business and registered office.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. So long as any of the indebtedness or obligations hereunder shall remain unpaid, the Borrower will provide, as soon as available, and in any event within ten (10) days after the end of each calendar month, a monthly report prepared by it and reviewed by the Third Party Consultant on the progress of development of the Project and achievement of Milestones in substantially the form of Exhibit E to the PUPA and in detail reasonably satisfactory to the Agent, including: (i) Milestone schedules, Milestones met and not met and, in the case of Milestones not met, the reasons why such Milestones were not met, targeted Milestones for the next month, and targeted Milestones for the next ninety (90) days, (ii) a report as to the progress of the Project, (iii) in the event of any material deviation or variance from the Project Budget, the reason for such material deviation and such other information reasonably requested by the Agent in connection therewith; (iv) any factors or events which have had, are having or could reasonably be expected to have a material adverse effect; (v) the status of all permits, licenses, franchises, approvals, authorizations, registrations, certificates, licenses, variances and similar rights obtained, or required to be obtained for the development of the Project, including with respect to those which have not been obtained, the dates of applications submitted or to be submitted and the anticipated dates of actions by applicable Governmental Authorities with respect thereto; (vi) a reporting on the number of WCE for each of the dairies, manure collection methods and quantum of supply to each dairy covered lagoon digester, and (vii) the status of all grants (including DDRDP grants) by Governmental Authorities for the Project, including with respect to grants that have not been obtained, the dates of applications submitted or to be submitted and the anticipated dates of action by applicable Governmental Authorities with respect to such grants.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. **Events of Default.** Each of the following events (each an "**Event of Default**") shall constitute an Event of Default:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. the Borrower fails to make any payment when due hereunder, whether upon demand by the Agent or Lenders, or otherwise;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. the Borrower fails to comply with, to perform, or to cause to perform, any other term, obligation, covenant or condition contained herein, any Loan Document or any of the related documents or to comply with or to perform any term, obligation, covenant or condition contained in any other agreement between Agent and/or Lender and the Borrower;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. any warranty, representation or statement made or furnished to Agent and/or Lender by Borrower or on Borrower's behalf hereunder or the related documents is false or misleading in any material respect, either now or at the time made or furnished or becomes false or misleading at any time thereafter;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. the Borrower or any of its affiliates or subsidiaries defaults under any loan, extension of credit, security agreement, purchase or sales agreement, or any other agreement, in favour of any other creditor or person that may materially affect any of Borrower's property or the Borrower's ability to repay this Credit Agreement or perform Borrower's obligations hereunder or any of the related documents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. the Borrower (i) becomes insolvent or generally not able to pay its debts as they become due, (ii) admits in writing its inability to pay its debts generally or makes a general assignment for the benefit of creditors, (iii) institutes or has instituted against it any proceeding seeking (x) to adjudicate it a bankrupt or insolvent, (y) liquidation, winding up, administration, reorganization, arrangement, adjustment, protection, relief or composition of it or its debts under any applicable law relating to bankruptcy, insolvency, reorganization or relief of debtors including any proceeding under applicable corporate law seeking a compromise or arrangement of, or stay of proceedings to enforce, some or all of the debts of such person, or (z) the entry of an order for relief or the appointment of a receiver, receiver-manager, administrator, custodian, monitor, trustee or other similar official for it or for any substantial part of its assets, and in the case of any such proceeding instituted against it (but not instituted by it), either the proceeding remains undismissed or unstayed for a period of 30 days, such person fails to diligently and actively oppose such proceeding, or any of the actions sought in such proceeding (including the entry of an order for relief against it or the appointment of a receiver, receiver-manager, administrator, custodian, monitor, trustee or other similar official for it or for any substantial part of its properties and assets) occurs, or (iv) takes any corporate action to authorize any of the above actions; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. a material adverse change occurs in Borrower's financial condition, or Agent and/or Lender believes the prospect of payment or performance of the obligations under this Credit Agreement is impaired.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17. **Remedies.** If any Event of Default shall have occurred and be continuing, then, and in any such event, the Agent may, without notice to the Borrower, declare all outstanding principal (and all accrued and unpaid interest thereon) and all other amounts owing hereunder and under the other Loan Documents to be forthwith due and payable, whereupon all outstanding principal hereof, all such accrued and unpaid interest and all such other amounts shall become and be forthwith due and payable, without presentment, demand, protest, notice of acceleration, notice of intent to accelerate, or further notice of any kind, all of which are hereby expressly waived by the Borrower; provided, however, that in the case of any event described in Section <u>16(e)</u>, all outstanding principal hereof, all accrued and unpaid interest thereon and all other amounts owing hereunder and the other Loan Documents shall automatically become and be due and payable, without presentment, demand, protest, notice of acceleration, notice of intent to accelerate, or any notice of any kind, all of which are hereby expressly waived by the Borrower.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18. **Costs and Expenses.** The Borrower agrees to pay the Agent all normal and customary fees, charges and expenses relating to the establishment and operation of this Credit Agreement and the Loan Documents and for services that may be provided to the Borrower by the Agent or Lender, including, but not limited to, debit fees, over-advance fees and wire transfer fees. The Borrower also agrees to reimburse the Agent, prior to and during the term hereof, for all reasonable out-of-pocket expenses incurred by the Agent or Lender in connection with the Loan Documents, including, but not limited to, filing fees, lien and judgment search fees, due diligence and collateral exam and inspection expenses, travel expenses, fees of outside auditors, bank fees, outside attorneys' fees, fees of appraisers and any other reasonable fees or expenses. The Borrower hereby agrees to indemnify the Agent and Lender forthwith upon demand therefor in respect of all such costs and expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19. **Security.** The Borrower and any other obligor under any Loan Document have granted or agreed to grant to the Agent (including, as may be applicable, for itself and/or in its capacity as administrative agent, collateral agent and representative for itself and other creditors), security interests, assignments or other interests as collateral security for the indebtedness hereunder, all of which secure the obligations owing hereunder. Each Lender irrevocably appoints the Agent to act on its behalf as administrative agent and collateral agent and, to the extent necessary, ratifies such appointment, and designates and authorizes the Agent as its attorney to take such actions on its behalf under the provisions of the Loan Documents and any ancillary document or security therefore and to exercise such powers and perform such duties as have been or may be delegated to the Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20. **Miscellaneous.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. <u>Waiver of Notice</u>. The Borrower waives presentment, protest, notice of dishonour, days of grace and the right of set-off. The failure of the Agent to exercise any rights hereunder in any particular instance shall not constitute a waiver thereof in that or any subsequent instance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. <u>Waiver and Amendment</u>. Any provision of this Credit Agreement may be waived, amended or modified only upon the written consent of both the Borrower and Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. <u>Restriction on Transfer</u>. This Credit Agreement may only be transferred in compliance with applicable provincial and federal laws. All rights and obligations of the Borrower and Agent shall be binding upon and benefit the successors, assigns, heirs, and administrators of the parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. <u>No Assignment</u>. This Credit Agreement or the rights or obligations hereunder may be transferred or assigned by the Agent or any Lender, provided that, unless a Default has occurred and is continuing, the Agent or applicable Lender shall be obliged to give the Borrower written notice of such transfer. The Borrower may not transfer or assign all or any part of its obligations hereunder without the prior written consent of Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. <u>Governing Law and Attornment</u>. This Credit Agreement shall be governed by and interpreted in accordance with the laws of the State of New York (without regard to the conflict of laws principles thereof). Without prejudice to the ability of the Agent to enforce this Credit Agreement in any other proper jurisdiction, the Borrower hereby irrevocably submits and attorns to the non-exclusive jurisdiction of the courts of the State of New York in connection herewith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. <u>Severability</u>. If any of the provisions of this Credit Agreement is held invalid, such invalidity shall not affect the other provisions hereof that can be given effect without the invalid provision, and to this end the provisions hereof are intended to be and shall be deemed severable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. <u>Notices</u>. All notices and other communications given to or made upon any party hereto shall, except as otherwise expressly herein provided, be in writing and mailed via certified mail, faxed or delivered to the respective parties in accordance with any subsequent written direction from the recipient party to the sending party delivered in accordance with this Section, or at such parties last known address or email or fax number. All such notices and other communications shall, except as otherwise expressly herein provided, be effective upon (i) delivery if delivered by hand; (ii) the third (3<sup>rd</sup>) Business Day after the date sent, in the case of certified mail; (iii) receipt, in the case of a fax or email.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h. <u>Definitions</u>. The following terms shall have the meanings set forth below.

------

**"Business Day**" means any day that is not a Saturday, Sunday, or other day on which banks in Toronto, Ontario are closed.

**"Change of Control**" means any situation or event by which Aemetis, Inc. (or its affiliate) is not the legal and beneficial holder, directly or indirectly, of 100% of the capital stock and equity interests (inc. warrants or options or convertible instruments) of the Borrower.

**"Free Cash Flow**" means, for any period, for the Borrower and each subsidiary, the sum of Operating Cash Flow plus (i) California Department of Food and Agriculture Dairy Digester Research and Development Program, California Department of Food and Agriculture, or any such alternative government grants; plus (ii) proceeds from any debt or equity financings or sales of Inflation Reduction Act credits; less (iii) interest or mandatory payments under Permitted Indebtedness (including hereunder which the Borrower pays in cash), less (iv) a working capital reserve of $1,000,000, in each case calculated for such period in accordance with GAAP.

**"GAAP**" means United States generally accepted accounting principles in effect from time to time.

**"Governmental Authority**" means any nation or government, any state, province, territory or other political subdivision thereof (whether federal, state, local or otherwise), any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies), any securities exchange and any self-regulatory organization.

**"Indebtedness**" means all obligations for borrowed money and all obligations evidenced by bonds, debentures, notes, loan agreement or other similar instruments, letters of credit, bankers' acceptances, guaranties, sureties and similar instruments, deferred purchase price arrangements (other than trade accounts in the ordinary course), capitalized amounts under capital leases, obligations under conditional sales agreements or other title retention agreements.

**"Investment**" means any beneficial ownership interest in any Person (including stock, partnership interest or other securities or other equity interests), and any loan, advance or capital contribution to any Person, or the acquisition of all or substantially all of the assets or properties of another Person.

**"Law**" any law, treaty, rule or regulation or determination of an arbitrator or a court of competent jurisdiction or Governmental Authority, in each case applicable to the applicable Person.

**"Lien**" means: (a) any mortgage, deed to secure debt, deed of trust, lien, hypothec, pledge, charge, lease constituting a capital lease obligation, conditional sale or other title retention agreement (or other lease having a substantially similar economic effect), or other security interest, hypothec, privilege, priority, security title, deposit arrangement or encumbrance of any kind in respect of any property of such Person, or upon the income or profits therefrom, (b) any arrangement, express or implied, under which any property of such Person is transferred, sequestered or otherwise identified for the purpose of subjecting the same to the payment of indebtedness or performance of any other obligation in priority to the payment of the general, unsecured creditors of such Person, (c) the filing of, or any agreement to give, any financing statement, publication or registration (or any of its equivalent in any jurisdiction) in respect of any of the foregoing (including any such precautionary filings), and (d) any other lien, charge, privilege, secured claim, title retention, garnishment right, deemed trust, encumbrance, hypothec, servitude, right-of-way, easement, privilege, priority or other right affecting Property, choate or inchoate, arising by any statute, act of law of any jurisdiction at common law or in equity or by agreement.

**"Loan Document**" means this Credit Agreement all other documents, instruments and agreements executed and delivered pursuant to or in connection with this Credit Agreement, (including without limitation certificates, guarantees, mortgages, security or collateral agreements) together with any and all extensions, renewals, amendments and modifications of any of the foregoing.

**"Milestones**" means the activities to be performed by the Borrower and its subsidiaries in relation to the Project, including the delivery of equipment, construction of the Project, entering into contracts with dairy farms for manure supply, biogas collection and discharge of effluents, obtaining pipeline rights of way, application and receipt of government grants from the State of California, the application for and receipt of permits, and budgets and time frames for all such activities.

**"Operating Cash Flow**" means for any period the sum of (i) all revenues of the Borrower and its subsidiaries, including revenues from the sale of natural gas production, sales of Low Carbon Fuel Standard (LCFS) credits, and sales of Renewable Identification Number (RIN) credits; less (ii) all operating costs, operating and maintenance fees, insurance costs, engineering and construction bonuses, taxes, in each case of the Borrower and its subsidiaries, and calculated for such period in accordance with GAAP.

**"Permitted Indebtedness**" means: (a) Borrower's Indebtedness under this Agreement and the other Loan Documents; (b) Indebtedness existing on the date hereof owing to Greater Commercial Lending; (c) unsecured Indebtedness to trade creditors incurred in the ordinary course of business, except for trade payables overdue by more than 120 days; (d) Indebtedness by a subsidiary of the Borrower to the Borrower; (e) Indebtedness incurred in the ordinary course of business under performance bonds, bid bonds, appeal bonds, surety bonds, performance and completion guarantees and similar obligations or in respect of worker's compensation claims, and reimbursement obligations in respect of any of the foregoing;.

**"Permitted Investments**" means: (a) Investments consisting of deposit accounts in which the Agent has a perfected security interest; (b) Investments by Borrower in Subsidiaries not to exceed $250,000 in the aggregate in any fiscal year Borrower; (c) Investments, in an aggregate amount not to exceed $250,000 in any fiscal year, consisting of travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business; (d) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business; (e) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not affiliates, in the ordinary course of business, (f) Investments consisting of amounts receivable and credit extensions by a Borrower to a subsidiary, (g) Investments consisting of the endorsement of negotiable instruments for deposit or collection in the ordinary course of business, and (h) so long as no Event of Default has occurred and is continuing or would result therefrom, any other Investments in an aggregate amount not to exceed $500,000 in the aggregate in any fiscal year.

**"Person**" means an individual, partnership, corporation (including a business trust), limited liability company, joint stock company, trust, unincorporated association, joint venture or other entity, or a government or any political subdivision or agency thereof.

"**Prime Rate**" means that rate of interest reported daily in the Wall Street Journal (or any successor publication) as the Prime Rate, as such rate may vary from time to time; provided that if such rate of interest becomes unavailable for any reason as determined by the Agent, such other rate of interest publicly announced by a reputable global bank in New York as its Prime Rate.

**"Project**" means the development, construction, completion and operation by the Borrower and its subsidiaries of a cluster of dairy covered lagoon digesters, H2S conditioning skids and related biogas pipelines, centralized HUB gas-cleanup and compression to RNG, any temporary boiler equipment, utility pipeline injection units, electricity conversion systems and RNG dispensing facilities to collect biogas from manure ponds located in California, which will be purified and compressed into utility-grade renewable natural gas and/or converted into other products for use Aemetis Inc.'s ethanol facility located in Keyes, California and for sale to transport fleets and utilities.

**"property**" means any interest in any kind of property or asset, whether real, personal or mixed, movable or immovable, tangible or intangible, including cash, securities, accounts and contract rights.

**"Third Party Consultant**" means Biogas Engineering Inc. or an equivalent partner providing similar guidance with respect to the Project.

**"WCE**" means a lactating dairy cow excreting Volatile Solids (VS) of 7.76kgs/day, with dry cows and heifers each considered approximately 0.5 times WCE.

&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Further Assurances</u>. The Borrower shall, as reasonably requested by the Agent, from time to time promptly execute and deliver further documents and take further action reasonably necessary or appropriate to give effect to the provisions and intent of this Credit Agreement.

[Signature Pages follows]

------

**IN WITNESS WHEREOF**, the Borrower has duly executed this Credit Agreement.

**AEMETIS BIOGAS LLC,**

as Borrower<u><sup>[1]</sup></u>

By: _______________________________

Name: Eric McAfee

Title: President

<u><sup>[1]</sup></u> Applicable Guarantors to be added at time of execution

ACKNOWLEDGED AND AGREED:

**THIRD EYE CAPITAL CORPORATION**

as Agent

Per: _________________________

Name: Arif N. Bhalwani

Title: Managing Director

**PROTAIR-X TECHNOLOGIES INC.**, as Lender

Per: _________________________

Name: Arif N. Bhalwani

Title: Chief Executive Officer

[to be inserted]

(*Agent and Lender Signature Pages follow*)

## Exhibit 31.1

**EXHIBIT 31.1**

CERTIFICATIONS

I, Eric A. McAfee, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q for the quarter ended March 31, 2026 , of Aemetis, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements, for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 7, 2026

---

| | |
|:---|:---|
| By: | /s/ Eric A. McAfee |
|  | Eric A. McAfee<br> Chair of the Board and Chief Executive Officer |

---

## Exhibit 31.2

**EXHIBIT 31.2**

CERTIFICATIONS

I, Todd Waltz, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q for the quarter ended March 31, 2026 , of Aemetis, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements, for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 7, 2026

---

| | |
|:---|:---|
| By: | /s/ Todd Waltz |
|  | Todd Waltz<br> Executive Vice President and Chief Financial Officer |

---

## Exhibit 32.1

**EXHIBIT 32.1**

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Aemetis, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Eric A. McAfee, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| By: | /s/ Eric A. McAfee |
|  | Eric A. McAfee<br> Chair of the Board and Chief Executive Officer |

---

Date: May 7, 2026

## Exhibit 32.2

**EXHIBIT 32.2**

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Aemetis, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Todd Waltz, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| By: | /s/ Todd Waltz |
|  | Todd Waltz<br> Executive Vice President and Chief Financial Officer |

---

Date: May 7, 2026